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There are a large number of protein-based therapeutics (biologics) that are FDA approved and 
available on the market for a number of diseases, and the number of biologics being approved 
every year has tripled in the past two decades. Biologics are highly attractive as therapeutic options 
due to their safety and efficacy; however, of all the marketed biologics, only several proteins are 
FDA approved for treatment of CNS. This is due to efficacy limitation of most proteins in the 
CNS. One of the reasons is due to the presence of the blood–brain barrier (BBB), which selectively 
limits protein drugs from entering the brain. Although the BBB is critical for things such as 
maintaining proper concentration of ions and preventing infection as well as harmful toxins from 
entering the brain, its selectivity makes it difficult to deliver diagnostic and therapeutic agents into 
the brain. Only a small fraction (i.e., 2%) of marketed small drugs has appreciable penetration into 
the CNS. Thus, there is a large unmet need to improve drug delivery to the brain for treatment of 
brain diseases such as multiple sclerosis (MS), Alzheimer’s disease (AD), Parkinson’s, and brain 
tumors. Currently, drugs that are not able to cross the BBB are sometimes administered via direct 
cranial injection or cerebral spinal fluid infusion; however, these are relatively invasive methods 
and they increase the risk for CNS infections. The goals of this project were specifically to 
investigate (i) if BBB modulation via the cadherin cyclic peptide, ADTC5, could be used to deliver 
brain-derived neurotrophic factor (BDNF) across the BBB to treat an experimental autoimmune 
encephalomyelitis (EAE), a mouse model of MS; (ii) if ADTC5 could also be used to deliver 
BDNF to treat an aggressive mouse model for Alzheimer’s disease (i.e., APP/PS1 mice); and (iii) 
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how ADTC5 can improve brain delivery a monoclonal antibody (mAbs) for evaluating its 
clearance from the brain in healthy mice. First, we observed that ADTC5 was able to significantly 
enhance the deposition of BDNF to have efficacies in the EAE and Alzheimer’s disease animal 
models. Compared to when BDNF was delivered alone or placebo, BDNF + ADTC5 improved 
clinical body scores and cognitive performance in EAE mice and APP/PS1, respectively. 
Additionally, both EAE and APP/PS1 mice that were treated with BDNF + ADTC5 showed 
increase levels of NG2 microglia, and EGR and ARC mRNA transcripts compared to BDNF alone 
or vehicle. In the EAE model, the NG2 glia was associated with increased levels of myelin. Second, 
we monitored monoclonal antibody (mAb) brain deposition and clearance after its brain delivery 
with ADTC5 peptide. In addition, the effect of ADTC5 in mAb depositions in other organs was 
also determined. We observed a rapid clearance of mAb from the brain after enhanced delivery by 
ADTC5 with two different phases. The estimated t1/2alpha and t1/2beta of IgG mAb were 0.34 ± 0.22 
h and 65.50 ± 12.09 h, respectively. This clearance was heavily facilitated by the liver and ADTC5 
did not affect antibody deposition into liver, spleen, kidney, lung, or heart. Overall, this project 
demonstrates a proof-of-concept that brain diseases can be effectively treated via brain delivery of 
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Chapter 1:  Methods of Delivering Molecules Through the Blood-Brain Barrier 
for Brain Diagnostics and Therapeutics 
1.1. Introduction: 
Every year, hundreds of thousands of people are diagnosed with brain disorders such as 
Alzheimer's, Parkinson’s, multiple sclerosis (MS), and brain tumors. However, because the brain 
is protected by the blood-brain barrier (BBB), there are few efficacious drugs available for treating 
these conditions. Although many agents have been developed for early diagnosis of brain diseases, 
these, too, cannot readily be delivered to the brain due to the presence of the BBB. The BBB plays 
a critical role in protecting the brain from various harmful substances (e.g., toxins) that may be 
present in the blood stream. The BBB is very selective, allowing only needed nutrients to cross 
while excluding many other molecules, including those that could be helpful, from the brain.  
Many modern biological drugs and diagnostic agents such as peptides, proteins (including 
antibodies), and oligonucleotides can be used to treat brain diseases; unfortunately, the majority 
of these molecules cannot cross the BBB. Large molecule biologics (e.g., antibodies, enzymes, 
cytokines, hormones) can be delivered to the brain only via intra-cerebral ventricular infusion 
(ICV) [1].  ICV is accomplished by drilling into the skull and surgically installing a port to deliver 
drugs directly to the brain; therefore, it is not a stress-free procedure for patients. In addition, this 
method involves a great deal of risk, as the brain becomes directly exposed to potential infection 
by pathogens. Thus, there is an urgent need to investigate and develop non-invasive and patient-
friendly alternative methods to deliver diagnostic and therapeutic agents to the brain. This chapter 
is focused on progress and new methods in delivering molecules for diagnosing and treating brain 
diseases. 
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1.2. Anatomy of the Blood-Brain Barrier (BBB): 
The BBB is composed of tightly packed vascular endothelial cells that are anchored to a 
basement membrane and surrounded by astrocytes (Figure 1.1A) [2]. These endothelial cells are 
connected at the intercellular junctions by “zipper” or “Velcro” proteins, which are divided into  
tight junctions, adherens junctions, and desmosomes regions (Figure 1.1B). These proteins form 
homophilic and/or heterophilic protein-protein interactions at these three regions to glue the 
endothelial cells forming the BBB microvessels. In this case, the surface proteins from one cell 
membrane of endothelial cells form a bridge with their respective counterparts on the surface of 
the opposing cell membrane [3-5]. The vascular endothelial cells are also decorated with various 
efflux pump molecules (i.e., P-glycoprotein, multi-drug-resistant protein) and proteolytic and/or 
metabolizing enzymes that act as gate keepers to prevent or degrade molecules from crossing the 
BBB. 
At the top of the intercellular junction membranes on the blood side of the BBB reside tight 
junctions or occludens junctions. They are connected by homophilic interactions of occludins, 
claudins, and junctional adhesion  (JAM) proteins (Figure 1.1B). These tight interactions prevent 
the permeation of molecules with hydrodynamic radius  larger than 11 Å through the intercellular 
junctions or paracellular pathways [6].  The adherens junction below the tight junction is linked 
by protein-protein interactions of cadherins, nectins, and platelet endothelial cell adhesion 
molecules (PECAM). These interactions are the primary adhesion force between two opposing 
cell membranes of the BBB. Thus, the tight junctions are the secondary seal of the intercellular 
junctions [2]. Finally, desmosomes are established below the adherens junctions and they produce 
homophilic desmocollin or desmoglein interactions as well as heterophilic desmocollin-
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desmoglein interactions. The desmocollins and desmogleins are in the cadherin family of proteins. 
It should be noted that there is crosstalk among all the intercellular junction proteins through their 
interactions with the cytoskeleton proteins. 
 
1.3. In Vitro Models to Study Brain Delivery of Therapeutic and Diagnostic Agents: 
1.3.1. In Vitro Models of the Blood−Brain Barrier: 
Because in vivo delivery of molecules into the brain is challenging, much effort has been 
invested in developing in vitro models for the BBB to rapidly identify molecules that can cross the 
BBB. Transport mechanisms of molecules across the BBB can be characterized into several 
categories. First, molecules can passively diffuse through the cell membranes of the endothelial 
cells, which is called the transcellular pathway (Figure 1.1A). It is well accepted that lipid-soluble 
nonpolar molecules can enter the brain via passive diffusion across the BBB. Unfortunately, some 
hydrophobic molecules that can partition to the cell membranes cannot cross the BBB because 
they are expelled by the efflux pumps (e.g., P-glycoproteins or Pgp) from the membranes back 
into the blood stream (Figure 1.1A). Second, molecules such as nutrients (i.e., folates, amino acid) 
and molecular carriers (i.e., transferrin) can permeate the BBB via receptor-mediated transport 
mechanism. This transport system involves a vesicular endocytosis process. Receptor-mediated 
systems have so far been accepted as one of the most promising approaches for noninvasive 
delivery of molecules across the BBB. Vesicular endocytosis without receptor involvement can 
also occur and this is called fluid-phase pinocytosis. Third, very small hydrophilic molecules and 
ions can penetrate the BBB via the intercellular junction in a process called paracellular pathway 
transport (Figure 1.1). 
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Various in vitro BBB models have been developed and widely used to rapidly evaluate the 
transport properties of molecules across the BBB during the discovery process. Compared to in 
vivo models, the in vitro BBB models are less expensive and more conducive to high throughput 
with reproducible results. Thus, the in vitro models are very useful for screening potential 
candidates in the initial discovery phase of therapeutic or diagnostic agents for the central nervous 
systems (CNS). However, the in vitro models have their own disadvantages. For example, some 
of the models have leaky tight junctions; therefore, they are not good models to study penetration 
of molecules through the paracellular pathway. It is recommended that in vitro studies should be 
coupled with in vivo studies using the top candidate molecules after in vitro screening.  It should 
be noted that, with appropriate choice and use of an in vitro model, the results from the in vitro 
model can be well correlated with the in vivo data [7,8]. 
A common in vitro model of the BBB consists of a cell monolayer isolated from primary brain 
endothelial microvessels or immortalized brain endothelial microvessels with many adaptations. 
Some in vitro models are composed of co-cultured cells with varying culture conditions to closely 
mimic the in vivo BBB. To generate the model, cerebral vascular endothelial cells from murine, 
rat, porcine, bovine, monkey, or human brains are isolated and cultured on the surface of a 
microporous membrane filter. The culture is fed with the appropriate nutrients to maintain the cell 
viability. The BBB co-coculture models were also developed using a combination of brain 
endothelial cells with pericytes, astrocytes, and neurons to mimic the anatomic and physiology 
complexity of the in vivo BBB. Normally, the BBB co-culture model has tight intercellular 
junctions with high trans-endothelial electrical resistance (TEER) values [9,10].  
The in vitro BBB cell monolayer contains components similar to those of the in vivo 
microvessel with tight intercellular junctions, functional transporters, surface and intracellular 
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metabolic enzymes, and efflux pumps. The limited porosity of the tight junctions in allowing 
movement of ions is reflected in the TEER value of the cell monolayer [11].  The TEER value 
determines the electrical resistance between the apical (AP) and basolateral (BL) sides of the 
monolayer. A high TEER value indicates very restricted movement of ions across the transcellular 
and paracellular pathways of the cell monolayer. The intercellular junction proteins act as 
gatekeepers of the paracellular pathways. Therefore, modulation of the interactions among the 
intercellular junction proteins of the BBB can result in leakiness of the tight junctions, which is 
reflected in  lowering of the TEER value due to the higher movement of the ions between the AP 
and BL sides. 
To mimic the BBB vasculature in a three-dimensional (3D) mode, the dynamic in vitro BBB 
(DIV-BBB) model has been developed to complement the monolayer BBB models. In this model, 
the endothelial cells are cultured in hollow fibers that resemble the blood vessels [12]. The DIV-
BBB model can be used to simulate in vivo blood flow with tunable shear stress. This is a good 
model to evaluate trans-endothelial trafficking of immune cells across the BBB and to study 
cerebrovascular physiology in various disease states [12]. Unfortunately, the DIV-BBB model is 
less suitable for evaluating transport of molecules in a high throughput manner because it is a 
difficult system to setup and establish. This model is also difficult to replicate because its 
generation requires special expertise.  
Newer microfluidic models called “BBB on a chip” have been developed to model the dynamic 
flow of the BBB using a smaller number of cells and lower amounts of samples. These models 
consist of human brain endothelial cells (hCMEC/D3) that are cultured on a porous membrane 
placed at the interface between two microchannels, allowing the cell culture medium to flow 
through two electrodes. The electrodes are used to continuously measure TEER values of the cell 
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monolayers. The hCMEC/D3 cell monolayers in the microfluidic device have a TEER value 
comparable to that of the well-established standard Transwell® [13].  This model can be used to 
simulate disruption of the BBB in neuroinflammatory diseases such as Alzheimer’s and 
Parkinson’s diseases. This study showed that the integrity of this BBB model was influenced by 
shear stress and inflammatory cytokines TNF-a as in neurodegenerative diseases. 
 
1.3.2. In Silico Models of the Blood−Brain Barrier: 
As an alternative to laboratory experimental methods, computational simulation or in silico 
methods have been developed as tools to predict favorable properties of molecules for crossing the 
BBB [14].  These computational methods can be used during the early stages of drug design to 
include desirable properties in the molecule for penetrating the BBB. Compared to in vitro and in 
vivo experiments, computational methods are fast and low cost methods for screening molecules 
that can cross the BBB [14].  The algorithm for a certain method was developed using LogBB and 
LogPS parameters from in vitro and  in vivo experiments of several known compounds [14]. 
LogBB is the concentration of drug in the brain divided by the concentration in the blood while 
logPS is the product of permeability and surface area. The unknown values for novel compounds 
are then derived from regression models [15]. Molecular dynamics simulations were used to 
calculate the one-dimensional diffusion coefficient for each molecule. A combination of diffusion 
coefficient and free energy landscape were used to determine the effective permeability (Peff) of a 
compound. The Peff was compared to LogBB and LogPS values to predict the ability of a molecule 
to cross the BBB [15]. This method has been shown to predict the BBB permeabilities of small 
molecules, and the predictions corelate with the experimental data [15]. 
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1.4. Methods to Improve Brain Delivery of Drugs and Diagnostic Agents: 
1.4.1. Transcellular Pathways: 
The traditional method to deliver drugs and diagnostic agents to the brain is via the transcellular 
pathway by which the molecule permeates from the blood stream into the brain via the transcellular 
pathway of the BBB. Unfortunately, this pathway is only viable for small molecules with 
appropriate physicochemical properties that follow Lipinski's Rules of Five [16-18]. In this case, 
a drug molecule should have a molecular weight of less than 500 Da with cLogP of less than five. 
The molecule should have fewer than five hydrogen-bonding donors and no more than ten 
hydrogen-bonding acceptors. Therefore, during the discovery process, medicinal chemists utilize 
these rules to guide them in designing drug candidates that can penetrate the BBB. Alternatively, 
medicinal chemists have cleverly created prodrugs that shield the hydrogen-bonding moieties in 
the molecule to improve their BBB permeation [19,20]. Although a molecule can satisfy the 
Lipinski rules, its penetration through the BBB can also be inhibited by the efflux pumps and/or 
degradation by metabolizing enzymes [21]. 
Due to their physicochemical properties or violation of the Lipinski’s rules, biologics such as 
peptides, proteins, and oligonucleotides cannot passively diffuse through the cell membranes of 
the BBB (i.e., paracellular pathway). Therefore, it is very challenging to deliver these types of 
molecules to the brain. There is a very limited number of peptides and proteins that can cross the 
BBB. These molecules can do this because they have transport receptors that carry them across 
the BBB. Therefore, many efforts are underway to find alternative routes and methods to deliver 
peptides, proteins, and oligonucleotides into the brain.  
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1.4.1.1. Prodrug Formation for Passive Diffusion through Cell Membranes of the BBB:  
Prodrugs have been developed to temporarily alter the physicochemical properties of 
hydrophilic and charged molecules (i.e., drugs or diagnostic agents) to improve their BBB 
permeation. The prodrugs are formed by adding promoieties to the functional group(s) (i.e., 
alcohol, acid, amine) of the drug to change physicochemical properties of the prodrug to make it 
more hydrophobic than the parent drug (Figure 1.2). Alternatively, prodrug formation can also be 
used to improve the solubility of hydrophobic and insoluble drugs in water [22,23]. Low water 
solubility prevents prevent drug administration in sufficient doses for oral and BBB 
bioavailability; thus, charged promoieties (e.g., phosphate ester) have been attached to the drug to 
produce salts of the prodrug to increase water solubility and dose. 
For charged drugs, the formation of uncharged prodrugs enhances their partition into cell 
membranes for passive diffusion across the BBB. Drugs with an acid functional group (pKa = 4.0) 
or a basic functional group (pKa = 8) functional group have a charge at physiological conditions, 
pH = 7.4; thus, they have low membrane permeation (Figure 1.2). In contrast, the formation of an 
ester prodrug for a drug containing a carboxylic acid removes the charge group; thus, the prodrug 
is expected to have a better BBB permeation than the parent acid drug. After crossing the BBB, 
the ester prodrug can be converted to the parent drug in the brain tissue by esterase enzyme(s) 
(Figure 1.2). This conversion traps the charged drug molecules in the brain tissues. There are 
several factors that prevent prodrug molecules from crossing the BBB. First, the prodrug could be 
recognized by the efflux pumps; thus, although it could partition effectively into the cell 
membranes, the efflux pumps would expel the prodrug from the cell membranes. Second, it cannot 
cross the BBB because of its premature conversion to the parent drug by an enzyme (i.e., esterases) 
in the systemic circulation or inside the endothelial cells. Third, the prodrug could be converted 
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by metabolizing enzymes (e.g., CYP450) to a more hydrophilic molecule to prevent its exit from 
the endothelial cells. 
Due to backbone amide bonds, peptides have a very high number of hydrogen-bonding donors 
and acceptors as well as a high molecular weight; these are the reasons that most peptides cannot 
readily cross the BBB [24,25]. One way to improve the partitioning of peptides or peptidomimetics 
into cell membranes is by forming cyclic peptide prodrugs (Figure 1.3) [24,25]. Formation of a 
cyclic peptide prodrug increases the number of intramolecular hydrogen bonds and lowers the 
hydrogen-bonding potential to surrounding water molecules. In addition, cyclic peptide prodrugs 
have rigid backbone structures with stable and compact conformations for better partitioning into 
cell membranes of the BBB. Cyclic prodrugs of RGD-peptidomimetics (e.g., Aggrastat) were 
designed using “trimethyl lock” phenylpropionic acid and acyl(oxy)alkoxy promoiety (Figure 1.3) 
[26-28]. RGD-peptidomimetics and Aggrastat cannot be delivered orally because they cannot 
penetrate the biological barriers due to their charges. The formation of a  cyclic prodrug (1) 
enhanced its cell membrane penetration 4.4 times compared to the parent RGD-peptidomimetic 
(2) in an in vitro cell culture model of the intestinal mucosa (i.e., Caco-2 cell monolayer) [26]. 
Similar results were found in the formation of cyclic prodrugs of the opioid peptides using 
trimethyl lock” phenylpropionic acid and acyl(oxy)alkoxy promoieties [29-31]. The advantage of 
cyclic peptide prodrugs is that they can be converted to the parent linear peptides by esterase after 
crossing the biological barriers in vitro and in vivo (Figure 1.3). The ester bond is clipped by 
esterase to form an intermediate followed by fast chemical reaction to release the parent compound 
(Figure 1.3). The disadvantage is that the cyclic peptide prodrug can be prematurely converted to 
the parent peptide before or during transport across BBB. The metabolism of cyclic peptide 
prodrugs by CYP450 while crossing the BBB can also be a hurdle for the development of these 
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compounds.  
 
1.4.1.2. Drug Conjugates for Receptor-mediated Transport through the BBB: 
Native transport receptors on the BBB have been exploited to improve drug delivery to the 
brain. Transferrin, insulin, IGF-I, IGF-II, angiotensin II, and natriuretic peptide receptor-7 have 
been targeted by their respective ligands to deliver drugs to the brain as protein–drug conjugates 
(Figure 1.2). Monoclonal antibodies (mAbs) against transferrin receptors (TfRs) on the luminal 
side of the BBB have been used to carry drug payloads into the brain by forming antibody-drug 
conjugates (ADC) [32-36]. This method has been referred to as the “Trojan horse” method. The 
mAb targets an epitope on the receptor that is distinct from the binding site of its endogenous 
ligand without interfering with the receptor function to shuttle its native ligand into the BBB 
endothelial cells or across the BBB [37]. The ADC is internalized and transported from the luminal 
through the vascular endothelial cells to the abluminal side of the BBB to exert the drug activity 
in the brain. 
Transferrin receptor (TfR) is an endogenous receptor that binds to holo-transferrin (hTf) 
carrying iron into the cells. Once the hTf-TfR complex enters the endosome intracellular, it 
experiences a pH change from 7.4 to 4.5–6.5, which triggers a the release of hTf from TfR and the 
release of the iron from hTf [37]. Then, the TfR is recycled back onto the cell surface. Thus, this 
mechanism has been explored to deliver anti-TfR mAbs such as OX26 and 8D3 mAbs that carry 
drugs or proteins across the BBB into the brain [37]. The I.V. administration of OX26 mAb 
resulted in its detection in the brain vasculature at 0.44% of the administered dose after injection. 
OX26 mAb was co-localized with Factor-VIII mAb that marked the branched capillaries of the rat 
brain [38-40].  OX26 mAb was deposited at the parenchyma region that was associated with 
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neurons and closed to the ventricular system. It was proposed that TfR was responsible for the 
transcytosis of OX26 mAb into the brain; the explanation given was that plasma clearance of OX26 
mAb was faster than the IgG control [41]. Using immunohistochemistry and capillary depletion 
methods, it was found that 90–95% of OX26 was in capillaries in the brain parenchyma, suggesting 
that the majority of the mAb was trapped inside the endothelial cells without crossing the BBB. 
Because the mAb was detected in cerebrospinal fluid (CSF), it was also suggested that the mAb 
entered the brain via cerebroventricular organs or the blood-CSF barrier. 
Administration of 8D3 anti-TfR mAb via I.V. injection indicated a brain deposition of the mAb 
at the 1-h time-point after injection; unfortunately, the extent of brain deposition was difficult to 
determine because capillary depletion experiments were not carried out [37,42,43]. Pegylated 
immunoliposomes (PILs) conjugated to 8D3 mAb and loaded with beta-galactosidase were found 
in various brain regions (septo-striatal, rostal, and claudal) of adult male Balb/c mice at 1–3 days 
after I.V. administration [44]. In another study, 1% of the I.V. administered dose per gram of 
biotinylated radiolabeled 125I-amyloid-beta 1–40 (Bio-125I-Aβ1-40) bound to streptavidin-8D3 (SA-
8D3) mAb was deposited in the brain of AppSwe/Psen1 double-transgenic Alzheimer’s Disease 
(AD) mice at the 1-h time point [45]. The peptide was found sequestered around the amyloid beta 
(Aβ plaques in the brain, suggesting the possibility of using this complex as a brain diagnostic tool 
for AD [45]. The low efficiency of the 8D3 mAb transport across the BBB into the parenchyma 
can be attributed to trapping of the mAb inside the BBB endothelial cells and the mAb localization 
in the brain parenchyma is still controversial [46]. Studies suggest that 8D3 mAb bound to 
vasculature endothelial cells. Confocal microscopy studies indicated that 8D3 mAb co-localized 
with collagen IV as a basal laminal marker, suggesting that the mAb traversed from the luminal 
(blood) to the abluminal side of the brain endothelial cells without releasing the mAb from the TfR 
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at the abluminal side. The inability to release the mAb was due to its high affinity to TfR [46]. 
One of the potential solutions to solve the problem of mAb release from TfR at the abluminal 
side is to design low affinity mAbs [46].  Alternatively, mAbs with pH-sensitive binding properties 
have been designed to improve their transcytosis. mAbs with lower binding to TfR at pH 5.5 than 
at pH 7.4 have higher transcytosis into the brain than mAbs that have higher binding at both pH 
5.5. and 7.4 [47].  The majority of mAb molecules with high affinity to TfR were found in the 
brain capillaries even 24 h after administration; in contrast, the low affinity mAbs were detected 
at the brain parenchymal and co-localized with a neuronal marker [46]. The high affinity mAb-
TfR complex degraded mainly in lysosomes compared to the low affinity complex; this is 
presumably due to the long residence time of the high affinity complex in the lysosomes [48]. This 
finding was congruent with in vivo observation where the high affinity mAb-TfR complex caused 
a low unbound fraction TfR on the cell surface. This low unbound fraction was due to the 
degradation of mAb-TfR complex in lysosomes. This was also one reason why the high affinity 
mAb had low brain exposure.  
To attenuate mAb affinity for TfR, a monovalent TfR mAb was developed for improving brain 
exposure and suppressing degradation in the lysosomes [49]. In this case, the Fc region of mAb31 
that recognizes amyloid-beta plaques was linked to one or two Fab fragment(s) of TfR mAb to 
produce sFab-mAb31 and dFab-mAb31 [49]. The majority of the monovalent sFab-mAb31 was 
transcytosed to the brain more efficiently than was divalent dFab-mAb31. sFab-mAb31 was 
distributed throughout the parenchyma and around Aβ plaques in the brains of PS2APP mice. The 
lysosome degradation of dFab-mAb31 was fast, suggesting one reason for its low transcytosis. 
dFab-mAb31 had no significant decoration of the plaques compared to control, which confirmed 
its slow transcytosis properties. In summary, the results suggest that mAb with a weak binding to 
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the carrier receptor is necessary for mAb release in the brain.  
Although extensive research efforts have been carried out to exploit the use of TfR to 
transcytose Tf mAb with conjugated drugs into the brain, moving this technology into the clinic 
has been challenging [37].  One of the reasons is the low efficiency of drug transport from blood 
to the brain. The degradation of mAb in endosomes as well as its trapping in the endothelial cells 
contribute to its low brain deposition. It is challenging to find an appropriate balance between 
binding affinity and release property of the mAb from TfR at the abluminal side of the BBB. The 
presence of TfRs in various tissues or organs could potentially elicit off-target side effects. 
Although this method has not yet reach clinical applications, it has contributed insights into 
mechanisms of actions and stimulated interest in evaluating various transport receptors as carrier 
molecules on the BBB.   
Insulin transporters other than TfR on the BBB have been exploited to deliver drugs, including 
proteins, into the brain by their conjugation to insulin [50,33]. Because insulin has a short half-life 
(t1/2= 10 min) in the systemic circulation, a high dose of the conjugate has to be administered to 
reach the needed dose in the brain [50,33].  One disadvantage of this method is that the insulin 
conjugate can cause hypoglycemia in the subject after systemic delivery [50]. Alternatively, a mAb 
targeted to an insulin receptor has been studied for delivering brain-derived neurotrophic factor 
(BDNF) to the brain. BDNF has been shown to induce neuroregeneration in animal models of 
brain diseases (i.e., MS, Alzheimer’s disease) when administered via ICV. In another study, the 
heavy chain C-terminus of the Tf mAb (HIRMab) was fused to BDNF to produce HIRMab-BDNF. 
The fusion produced binding affinities similar to Tf mAb to TfR and BDNF to TrkB receptors 
with affinity similar to that of BDNF. The results suggest that fusion of the two proteins did not 
influence the binding affinity of each protein to its respective target receptor [33]. Three hours 
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after I.V. administration of 3H-HIRMab-BDNF in rhesus monkeys, a significantly higher brain 
deposition of 3H-HIRMab-BDNF (24 ng/g brain) than 3H-IgG2a was observed in brain 
homogenates. It was found that the amount of fusion protein in the brain was tenfold higher than 
that of endogenous BDNF control, indicating that the mAb enhanced BDNF delivery into the brain 
[33]. 
 
1.4.1.3. Liposome-mediated Brain Delivery: 
The abilities of different ligands to deliver liposomes into the brain were investigated by 
targeting their respective receptors on the BBB. Ligands such as proteins (i.e., transferrin, RI7217 
mAb, CRM19) or peptides (i.e., ICOG133, angiopep-2) were used to decorate the surface of 
liposomes [51-53]. The receptors for these ligands are found on the endothelial cells of the BBB. 
Both transferrin and RI7217 mAb bind to TfR on the BBB. It is well known that TfR transports 
iron on transferrin (Tf) into the brain. RI7217 mAb has been shown previously to transport 
loperamide across the BBB [54].  CRM-197 is a ligand for diphtheria toxin receptor (DTR) and 
heparin-binding epidermal growth factor (HB-EGF) expressed on the BBB surface, and CRM-197 
is a non-toxic mutant of diphtheria toxin (DT) that contains a single point G52D mutation. 
COG133 peptide is derived from apolipoprotein E (apoE) and COG133 peptide binds to low-
density lipoprotein receptor (LDLR). LDLR is responsible for transporting cholesterol and lipids 
into CNS [55]. Angiopep-2 peptide binds to low-density lipoprotein receptor-related protein 1 
(LRP1). The liposomes were decorated with targeting ligands via a maleimide PE linker embedded 
in the liposomes. The liposomes were composed of EPC, cholesterol, EPG, and MPB-PE with a 
molar ratio of 6.5:2.6:0.8:0.1 [56]. 
Mouse brain endothelial cells (bEnd.3) and human (hCMEC/D3) brain endothelial cell 
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monolayers were used to evaluate the receptor-mediated endocytosis of 3H-labeled liposomes 
decorated with different ligands by incubating them at 4 oC or 37 oC for 1 h. The results showed 
that only liposomes decorated with CRM-197 have significant binding compared to control 
liposomes in both endothelial cells. In contrast, liposomes decorated with RI7217 mAb binds only 
to human (hCMEC/D3) brain endothelial cells; these liposomes were engulfed by hCMEC/D3 
cells significantly better than liver and kidney cells, indicating the selectivity of the hCMEC/D3 
cells. COG133-labeled liposomes did not bind and cross the BBB in the in vitro and in vivo models, 
suggesting that COG133 peptide does not have the necessary sequence or properties for binding 
and uptake by the LDLR. Although angiopep-2-paclitaxel conjugate has been shown to cross the 
BBB, there was no uptake of angiopep-2 liposomes by the endothelial cells; this could be due to 
the density and/or accessibility of peptides on the surface of liposomes for recognition by LRP1 
on the endothelial cells. It has been shown previously that ligand density has an important role in 
the targeting efficacy of nanoparticles or liposomes [57], and different ligands can have different 
optimal ligand densities to elicit the same binding outcomes [58].  
Because RI7217 liposomes were engulfed by hCMEC/D3 cells, further studies were carried 
out in vivo. RI7217 liposomes labeled with non-exchangeable [3H]cholesteryl hexadecyl ether (5 
Ci/mol total lipid) were administered via I.V. in mice and, after 12 h of circulation time, the mice 
were sacrificed to collect the blood, brain, and other major organs [51]. The liposomes were cleared 
from the blood in a 12-h time period. More RI7217 liposomes were found in the brain fractions 
compared to untargeted liposomes after capillary depletion. There was no significant difference in 
the uptake of RI7217 over untargeted liposomes in any other organs, suggesting selectivity of 
RI7217 for the brain [51]. The RI7217 liposomes were found in significant amounts in 
parenchyma, cerebrum, and cerebellum. The amounts of RI7217 liposomes in the brain 
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parenchyma fraction were 4.3 and 2.6 times higher than the untargeted liposomes at 6- and 12-
hour time points after administration, respectively.  The amount of RI7217 liposomes was 10-
times higher than that of untargeted liposomes in the brain capillary fraction, suggesting that 
RI7217 liposomes bound to TfR on the BBB. Finally, a fraction of the RI7217 liposomes crossed 
the BBB endothelial cells into the brain. In conclusion, the amount of liposomes that reached the 
brain were about 0.18% after 12 h, which was considered a low amount of delivered liposomes 
[51]. It has been suggested that this delivery method be used only for very potent drugs such as 
opioids, which need a very low dose in the brain. 
 
1.4.1.4. Brain Delivery of Nanoparticles: 
Nanoparticles have been exploited for delivering molecules to the brain, and the types of 
nanoparticles such as shapes, sizes, and physical properties of the particles may play a significant 
factor in their uptake into the brain. The presence of targeting ligands can help direct the 
nanoparticles to the BBB and possibly into the brain. Ligands that can enhance the uptake of 
liposomes into the brain can also be used to deliver different types of nanoparticles (e.g., 
polymeric, albumin, etc.). 
Magnetic nanocrystals of Fe3O4 have been used as a magnetic resonance contrast agent for 
early detection of brain diseases. Nanoparticle surfaces have been decorated with lactoferrin (Lf) 
to make Lf-Fe3O4 nanoparticles. Lf is involved in host defense mechanisms against severe 
inflammation or infection and normally accumulates in the brains of neurodegenerative disease 
patients [59,60]. Lactoferrin receptors (LfR) are expressed on the BBB endothelial cells for 
transcytosis of Lf into the brain [59]. The uptake of Lf by LfR is more efficient than those of 
transferrin or OX-26 antibody by TfR; thus, Lf is potentially a better ligand to deliver nanoparticles 
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across the BBB [61]. Lf was conjugated to the nanoparticles via the one of the carboxylic acid 
terminals of the polyethylene glycol (HOOC-PEG-COOH) that coating the surface of iron 
nanoparticles. The role of PEG molecules is to improve water solubility and biocompatibility of 
the particles as well as to reduce protein adsorption, reticuloendothelial system (RES) uptake, and 
immunogenicity stimulation [60]. At all particle concentrations, PEG-coated Fe3O4 nanoparticles 
without Lf (untargeted nanoparticles) disrupt the tight junctions of the primary porcine brain 
capillary endothelial cell (PBCEC) monolayers as indicated by decreasing TEER values of cell 
monolayers. In contrast, incubation of Lf-Fe3O4 nanoparticles maintained the monolayer integrity 
at concentrations of 0.04 and 0.1 mg Fe/mL. Lf-Fe3O4 nanoparticles disrupt the BBB tight junction 
integrity at a high particle concentration (0.3 Fe mg/mL). The results suggest that Lf-conjugation 
suppresses the BBB tight junction disruption by untargeted nanoparticles. 
The BBB transport properties of Lf-Fe3O4 (Lf-labeled) nanoparticles were evaluated in vitro 
and in vivo. In vitro incubation of Lf-Fe3O4 nanoparticles (0.04 and 0.1 Fe mg/mL) for 18 h on the 
apical (AP) side of PBCEC cell monolayers resulted in observation of the transported nanoparticle 
at the basolateral (BL) side as determined using atomic absorption spectrometer (AAS). About 
22% of the nanoparticles crossed the BBB monolayers. The nanoparticle transport was inhibited 
by excess Lf alone (16x) from 22% to 1% transport, suggesting that the particle was transported 
via LfR-mediated transcytosis. The Lf-Fe3O4 nanoparticles were evaluated in vivo using SD rats, 
and the brain distribution of the nanoparticles was detected using a 7.0 T animal magnetic 
resonance imaging (MRI) instrument. Coronal and axial T2 relaxation data were collected at pre- 
and 24-h post-tail vein injections to detect nanoparticle deposition in the brain. Axial T2 contrast 
images showed that both Lf-labeled and unlabeled particles reached the brain, but the Lf-labeled 
nanoparticles showed greater contrast than the unlabeled particles in the thalamus, brain stem, and 
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frontal cortex. These results suggest that the labeled nanoparticles traverse the BBB and access the 
brain via LfR-mediated uptake. There was a higher localization of Lf-labeled nanoparticles in the 
brain microvessels compared to unlabeled nanoparticles. Because the unlabeled nanoparticles were 
also found in the brain, their transport across the BBB could be due to the disruption of the BBB 
intercellular junctions [60]. 
 
1.4.1.5. Exosome-mediated Brain Delivery: 
Exosomes are 40–100 nm nanosized bubble-like particles found in body fluid that are secreted 
by various types of cells [62]. They are formed via invagination of multi-vesicular body followed 
by fusion of cell plasma membranes, but do not contain lysosomes or mitochondria. The surfaces 
of exosomes are decorated with endogenous proteins from the producing cells, and these exosomes 
can be exploited to target certain cells or tissues. The most exciting characteristic of exosomes is 
that they can travel from one cell to another to release their contents (e.g., proteins, RNA) in the 
intracellular space of destination cells. There are several other unique exosome properties that are 
beneficial for drug delivery vehicles. First, small-to-large molecules can be loaded into exosomes 
for delivery. Second, surface proteins on exosomes can be used to direct them to intended target 
cells for uptake. Third, exosomes have high plasma stability with a long half-life in the systemic 
circulation and various tissues [62]. 
Rhodamine-loaded exosomes have been delivered to the brains of zebrafish and fluorescence 
dye was detected in the brain tissue, excluding the vasculature network [63]. The doxorubicin-
loaded exosomes have also been shown to target DiD-labeled U-87 MG cancer cells in zebrafish 
brain. In addition, five days after treatment with doxorubicin-loaded exosomes, the tumor size in 
the brains of zebrafish was reduced. In another example, siRNA-loaded RVG exosomes were 
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delivered to wild-type mouse brain and BACE1 enzyme expression that is important in 
Alzheimer’s disease was suppressed [64]. This delivery of this RVG exosomes was relatively 
selective to target siRNA into the brains and avoided uptake by tissues outside of the brain [62]. 
In summary, although the exosome delivery system seems better than other synthetic drug 
carriers, this technology still has many challenges to overcome. The first is to identify the proper 
donor cells to generate the desired and appropriate exosomes. Second, it is difficult to find the 
appropriate method to efficiently load the drug into exosomes. Third, the pharmacokinetic 
properties of exosomes have been challenging to determine. Fourth, it is still difficult to provide 
consistent targeting molecules on the surface of exosomes. Finally, the ability to scale up exosome 
production and to load them for clinical use are still barriers that need to overcome. 
 
1.4.1.6. Viral Vectors Brain Delivery: 
Delivering genes across the BBB faces the same challenges as delivering conventional 
therapeutics. Due to the chemical and enzymatic instability of genes, a high dose of genes is 
required for their successful therapeutic use; unfortunately, this high dose in the systemic 
circulation could increase side effects such as hepatoxicity [65].  Viral vectors have been somewhat 
successful in delivering genes to various tissues other than the brain; however, this success has 
been tainted by viral infections in treated patients due to impurity of the viral vectors. The viral 
vectors exploit their viral infection mechanisms to enter into the brain by crossing the BBB. To 
enter the brain, viral vectors utilize surface proteins to bind target receptors on the endothelial cells 
for crossing the BBB. The vectors also use their own surface proteins to bind receptors on the 
target cells to deliver genes into the cells. Inside the cell, the viral vectors follow the intracellular 
trafficking process and escape the endosome to enter the nuclear of cells. Finally, the capsid is 
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unpacked and the genome is inserted in the cell nuclear to initiate transcription and translation 
processes.  
Non-pathogenic recombinant adeno-associated viruses (rAAVs) with certain capsid serotypes 
have been shown to cross the BBB and deliver genetic material to neurons and astrocytes in the 
brain. Thus, AAVs have been developed to carry 4.7 kb single-stranded DNA for gene expression 
in target-host cells. To design viral vectors that can cross the BBB for delivering the genes to the 
desired location or cells in the brain, the 60 viral proteins (VP) with sequence diversity were used 
to assembled to make AAVs [66]. AAV1 and AAVrh.10 are viral vectors that share 85% sequence 
homology; they were discovered through DNA shuffling. AAV1 viral vector did not cross the 
BBB and can transduce the brain vasculature only; in contrast, AAVrh.10 vector has a different 
capsid domain to traverse through the BBB [65]. To evaluate whether viral vectors could cross the 
BBB, a GFP-expressing cassette was packaged into AAV1, AAVrh.10, and six other chimeric 
variants of viral vectors. Then, they were administered via I.V. injections at a dose of 5 × 1011 viral 
genomes (vg)/per mouse) into 6- to 8-week-old mice. Three weeks later, the brains were isolated 
and subjected to immunostaining. It was found that AAV1 vector was located only in the brain 
vasculature while AAVrh.10 showed robust GFP transduction in neurons, glia, and endothelial 
cells. 
An AAV1RX vector was developed by grafting eight residues from AAVrh.10 onto AAV1 to 
make this viral vector able cross the BBB. This vector can deliver genes to selectively transduce 
neurons, indicating that the eight residues have a critical role in allowing the vectors to penetrate 
the BBB. Unfortunately, AAV1RX viral vectors can also transduce liver and cardiac tissues in a 
manner similar to that of AAV1, suggesting that other structural domains of the AAVrh.10 capsid 
play a role in a systemic transduction profile. From the results, it is uncertain whether this 8-residue 
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footprint is sufficient to selectively deliver genes to the brain and facilitate a transduction profile 
similar to that of  AAVrh.10 vector. 
AAV1R6 and AAV1R7 are two viral vectors that were designed from AAV1 with 97% 
identical amino acid sequence that have an important 22-amino acid residue derived from AAVrh 
and AAVrh.10. This amino acid residue is important for crossing the BBB. The design was based 
on the overall beta-barrel structure of core viral protein 3 (VP3) with VP7 antiparallel beta-strands 
connected by interlocking loop regions. The highly variable and surface-exposed loop regions on 
AAV capsids have been modified to control tissue tropism, transduction profile, and antigenicity 
[66,67]. Similar to the AAVrh.10 vector, AAV1R6 and AAV1R7 vectors have a robust 
transduction on cortical neurons and other brain regions; in contrast, they reduced transduction in 
glia and vasculature when compared to AAVrh.10. This result confirms that AAV1R6 and 
AAV1R7 vectors can cross the BBB. AAV1RX6 and AAV1RX7 have the potential for developing 
gene therapies against neurological disorders including spinal muscular atrophy. These vectors do 
not target peripheral organs (i.e., liver and cardiac tissues); thus, they avoid potential hepatoxicity 
side effects. Therefore, future successful clinical applications of these vectors will rely on their 
efficacy in large animals such as non-human primates [65,67]. 
 
1.4.2. Brain Delivery of Molecules through Paracellular Pathways of the BBB: 
One alternative method to deliver molecules through the BBB is via the paracellular pathways 
by increasing the opening or porosity of the tight intercellular junctions. One of the most successful 
methods in the clinic to deliver molecules through paracellular pathways is osmotic delivery, 
which has been used to deliver anticancer drugs to treat brain tumor patients [68-76]. The osmotic 
method involves injecting a hypertonic solution of mannitol into the carotid artery to shrink the 
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BBB endothelial cells and creates a disruption of the tight intercellular junctions. This disruption 
generates larger pores in the intercellular junction to increase the penetration of anticancer drugs 
into the brain [75,77,73]. It should be noted that the hypertonic mannitol works via increasing the 
osmotic pressure in the blood stream and does not disrupt the intercellular junction proteins in a 
selective manner.  
Several methods have been developed to increase the porosity of the intercellular junctions by 
disrupting protein-protein interactions in the intercellular junctions. Peptides derived from the 
sequences of the extracellular domains of intercellular junction proteins have been developed to 
selectively inhibit protein-protein interactions in an equilibrium fashion to increase permeation of 
molecules through the BBB. Claudin and occludin peptides have been shown to modulate the 
intercellular junctions  of the biological barriers in vitro and in vivo [78-80]. The C1C2 peptide 
(Table 1.1) derived from claudin-1 can deliver opioids and tetrodotoxin into rat brains [78]. The 
C1C2 peptide can open the BBB for extended period of time (i.e., 3 days); however, this long 
period of opening of the BBB may not be desirable. Thus, further investigation is needed to find 
peptide derivatives that can modulate the tight junctions of the BBB for a shorter period of time. 
Several peptides that are related to tight junction proteins were designed to increase the 
paracellular porosity of the biological barriers. OCC2 peptide (Table 1.1) derived from loop 2 of 
chick occludin was active in disrupting the tight junctions and decreasing the TEER values of A6 
epithelial cell monolayers. OCC2 peptide also enhanced paracellular permeation of dextran-3000 
and 40,000 across the A6 epithelial monolayers. However, OCC2 has not been evaluated to 
improve the delivery of molecules across the BBB in in vitro and in vivo models. A peptide called 
AT-1002 (Table 1) that was derived from zonula occludens toxin (ZOT) protein improved the 
paracellular delivery of low molecular weight heparin orally. AT-1002 disrupts the tight junctions 
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of Caco-2 and brain endothelial cell monolayers. C-CPE peptide from a microbial toxin fragment 
can modulate claudin-3 and -4 in tight junctions of Caco-2 but not in brain endothelial cell 
monolayers. PN-78 and PN-159 peptides (Table 1.1) were discovered from phage display studies, 
and both peptides significantly lowered the TEER values of Caco-2 and brain endothelial cell 
monolayers. PN-159 was very potent in enhancing the delivery of fluorescein and albumin through 
Caco-2 and brain endothelial cell monolayers.  
Peptides (i.e., HAV and ADT peptides) that are derived from the extracellular 1 (EC1) domain 
of E-cadherin have been shown to modulate in vitro biological barriers (i.e., Caco-2 and MDCK 
cell monolayers) [81-83]. HAV and ADT peptides can modulate the BBB intercellular junctions 
and enhance brain delivery of molecules in mice and rats [84-89]. The proposed mechanism of 
action of HAV and ADT peptides is via their binding to the EC1 domain of cadherins. 
Heteronuclear multiple quantum coherence (HMQC) NMR spectroscopy experiments show that  
HAV and ADT peptides bind to different binding sites on the EC1 domain of E-cadherin [90]. 
HAV6 and ADTC5 peptides enhanced the brain delivery of 14C-mannitol as a paracellular marker 
[86,87]. In addition, HAV6 peptide enhances the brain delivery of efflux pump substrates such as 
3H-daunomycin into rat brains using in-situ rat brain experiments [84] and IRdye R800 into the 
mouse brain after I.V. administration [87]. These results suggest that cadherin peptides can be used 
as an alternative way to deliver efflux pump substrates to the brain.  
To further evaluate the BBB modulatory activity of cadherin peptides, an  MRI contrast agent, 
Gd-DTPA, was delivered via I.V. administration together with HAV6 or ADTC5 peptide in mice; 
the brain depositions of Gd-DTPA were detected using MRI in living animals [86,87]. The results 
showed that the deposition of Gd-DTPA was observed in the brains within 3.0 min after 
administration, and both peptides significantly enhanced brain delivery of Gd-DTPA compared to 
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a control vehicle in mice.  The duration of tight junction modulation was evaluated using MRI; in 
this case, the HAV6 peptide was administered alone, and Gd-DTPA was administered via i.v. route 
after 1 h [87]. The result showed that there was no significant enhancement of Gd-DTPA compared 
to control, suggesting that the duration of opening of the BBB by HAV6 peptide was less than 1 
h.  A similar study showed that ADTC5 peptide could open the BBB between 2 to 4 h, which is 
longer than when using HAV6 peptide [86]. 
ADTC5 peptide enhances the brain delivery of 8-mer cIBR and 12-mer cLABL peptides in 
rats and mice, respectively [89]. The deposition of intact cIBR peptide can be detected in rat brain 
by LC-MS/MS.  HAV6 and ADTC5 peptides have been shown to significantly enhance the 
delivery 65 kDa albumin conjugated with Gd-DTPA (i.e., galbumin) compared to control peptide 
or PBS as detected by MRI. The deposition of the protein could be detected in the brain 3.0 min 
after administration [89]. For a large protein such as galbumin, HAV6 could be used only when 
both HAV6 and galbumin were delivered simultaneously; however, a 10-minute delay of galbumin 
administration after delivery of HAV6 did not enhance galbumin brain delivery. In contrast, 
ADTC5 was able to enhance the delivery of galbumin into the brain after a 10-minute delay; 
however, a 40-minute delay of galbumin after ADTC5 injection did not show any enhancement of 
brain delivery. The results suggest that the opening of the BBB by cadherin peptides is short for 
large molecules compared to the opening for small molecules. It is proposed that cadherin peptides 
generate large, medium, and small pores in the intercellular junctions of the BBB and the large 
pores rapidly collapse to medium and small pores followed by the collapse of medium pores to 
small pores in a time-dependent manner.  
In summary, many potential disruptors of the intercellular junctions of the BBB have the 
potential to enhance the delivery of diagnostic and therapeutic molecules into the brain. The 
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applicability and safety of these modulators to deliver therapeutic and diagnostic agents to the 
brain still needs further investigation. The next step is to use these modulators to deliver functional 
molecules to the brains of animal models of brain diseases.  
 
1.5. Current Methods to Diagnose Brain Disease: 
Many imaging methods (e.g., MRI, X-ray, CATscan) have been used to diagnose brain 
diseases (i.e., Alzheimer’s, Parkinson’s, multiple sclerosis, stroke, and brain tumors). Some of 
these methods utilize molecular imaging techniques by delivering highly sensitive probes into the 
brain in a non-invasive manner. These probe molecules can be powerful detection tools for 
detecting changes in the brains during the progression of brain diseases; these changes include the 
brain cellular activities and morphologies as well as the protein compositions to diagnose brain 
diseases in clinical and preclinical settings. Early detection of brain diseases is important for 
halting their progress; therefore, the use of specific and sensitive molecular imaging techniques is 
necessary. In both preclinical and clinical studies, several molecular imaging techniques such as 
magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission 
computed tomography (SPECT), and optical imaging techniques including near-infrared (NIR) 
fluorescence imaging have been greatly advanced for diagnosing brain diseases ex vivo and in vivo 
[91].  
Neuroinflammation can be a common sign of brain diseases such as stroke, multiple sclerosis, 
Alzheimer’s, malignant cancer, and Parkinson’s. The neuroinflammation process activates 
inflammatory immune cells that infiltrate the brain along with the upregulation of inflammatory 
cytokines. Therefore, changes in the balance between the activation of inflammatory and 
regulatory immune cells in the brain can be the target of diagnostic agents for brain disorders. 
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Many current diagnostic molecules for brain diseases are limited to small hydrophobic molecules 
that can cross the BBB. These small molecules typically have a molecular weight less than 500 Da 
and have high binding capacity to the target tissue(s) in the brain. In contrast, many peptides, 
nucleotides, and proteins (e.g., enzymes and antibodies) are molecules that have high selectivity 
to bind cellular components of the brain (e.g., proteins and sugars) for detecting changes in the 
brain. Unfortunately, these types of molecules cannot be delivered to the brain because they cannot 
cross the BBB. Thus, if these types of molecules could be delivered to the brain, they could be 
utilized to improve the diagnostics and treatments of brain diseases. Several methods used in 
attempts to deliver them to the brain have been described above. 
The infiltration of leukocytes into the brain during inflammation occurs via extravasation 
through the intercellular junctions of the BBB [92]. This process involves various cell adhesion 
molecules on the leukocytes as well as the on the endothelial cells of the BBB [93]. The process 
of extravasation of immune cells is initiated by rolling of these cells of the surface of endothelium 
mediated by L- and E-selectins. When the immune cells stop rolling, they firmly adhere to the 
endothelial cells, which are mediated by ICAM-1 and VCAM-1 immunoglobulins on the 
endothelial cells that bind to LFA-1 (αLβ2) and VLA-4 (α4β1) integrins, respectively, on the surface 
of leukocytes [93,92]. Natalizumab, a monoclonal antibody that binds to α4-subunit of VLA-4 
integrin, is being  used to treat MS because it can prevent adhesion of immune cells to the BBB. 
Therefore, it prevents brain infiltration of immune cells to suppress disease exacerbation in MS 
patients. This indicates upregulation of cell adhesion molecules (e.g., ICAM-1) on the endothelial 
cells of the BBB, and the increased expression of cell adhesion molecules on the BBB endothelial 
cells of MS patients can be explored as diagnostic markers of MS [94]. 
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1.5.1. Magnetic Resonance Imaging (MRI): 
MRI has been used extensively to diagnose brain diseases. The experimental autoimmune 
encephalomyelitis (EAE) disease in mice has been used as an animal model for multiple sclerosis 
(MS). In animal models and patients with MS, MRI detects T1 black holes in the brain and spinal 
cord [95,96].  In EAE animals, T1- and T2-weighted images using high-resolution spin-echo 
sequences are being used to determine the lesion loads. With the help of MRI contrast agents (e.g., 
Gd-DTPA, Gd-DOTA), Type A or B lesions can be detected where the hypo-intensity in both T1- 
and T2-weighted MRI is usually related to Type A lesions. In contrast, Type B lesions usually are 
correlated with the observation of hyper-intensity in T2-weighted MRI with reduced signal of T1-
weighted MRI [97]. A high infiltration of inflammatory cells and myelin loss are indications of 
Type A lesions; moderate inflammatory cell infiltration and myelin loss correspond to type B 
lesions [97]. 
The brain deposition of an MRI contrast agent, Gd-DTPA, has been used to assess the 
development of MS in patients as well as in EAE animal models. Prior to the infiltration of immune 
cells, the BBB breakdown is manifested in the leakiness of the paracellular pathways, allowing 
higher Gd-DTPA permeation through the BBB. In addition, ultra-small particles of iron oxide 
(USPIO) have been used to track brain infiltration of macrophages and monocytes as a diagnostic 
for the development of MS disease. In this case, USPIO 7228 (600 μmol iron oxide/kg) was 
administered via I.V. injection into EAE mice. Because macrophages and monocytes can engulf 
the particles in the blood stream, the level of immune cell infiltration of the brain can be quantified 
by determining the accumulation of iron oxide particles in the brain tissue using MRI [98]. T2 
maps of MRI using a spin-echo sequence acquired 24 h after injection were used to determine the 
amount of iron oxide particles in the brain. One of the limitations of using USPIO particles is that 
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it is difficult to differentiate the brain infiltration between pro-inflammatory and anti-inflammatory 
cells [99]. 
Iron oxide particles have different sizes that can be divided into ultra-small superparamagnetic 
iron oxide (USPIO, 10–50 nm), superparamagnetic iron oxide (SPIO, 50–100 nm), and 
micrometer-sized iron oxide (MPIO, >1 μm). These particles are usually coated with a polymer 
shell containing citrate or dextran, which can be detected as a negative contrast on T2-weighted 
MRI images due to their large negative magnetic properties [91]. The USPIO image in MRI has 
also been used to detect lesions that have low T2 signal in EAE. As mentioned previously, the 
presence of USPIO in the brain due to phagocytosis by immune cells was confirmed using ex vivo 
brain histological studies. The MRI signal enhancement from USPIO is normally compared to Gd-
DOTA enhancement because Gd-DOTA brain deposition is due to paracellular BBB breakdown. 
The USPIO lesion volume at the peak of disease in EAE can be correlated with stages of 
inflammation, phagocyte infiltration, demyelination, and axonal damage in the central nervous 
systems [100]. Iron oxide particles have also been used to track C6 cells in the in vivo rat glioma 
model because C6 cells have been shown to phagocytose nanoparticles with a diameter of 20 nm 
[101]. This method was later used in humans suffering from glial tumors, and the tumors were 
found to have high iron oxide signal compared to the Gd-DTPA signal [101]. 
The upregulation of VCAM-1 expression on the BBB endothelial cell during 
neuroinflammation can be determined using MPIO decorated with anti-VCAM-1 mAb (VCAM-
1-MPIO) [102]. In this case, the animals were treated with IL-1β cytokine intracerebral injection 
for inducing neuroinflammation. The accumulation of VCAM-1-MPIO was detected by T2-signal 
of MRI caused by particles bound to the BBB endothelium. This particle accumulation was 
inhibited when anti-VCAM-1 was delivered prior to the delivery of VCAM-1-MPIO, indicating 
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that the particles bind specifically to VCAM-1 on the surface of endothelium [102]. In EAE mice, 
VCAM-1-MPIO particles were detected in all visible lesions that were detected using Gd-DTPA. 
However, VCAM-1-MPIO can also detect additional lesions that correspond to leukocyte 
infiltration across the BBB [103]. 
Similar to VCAM-1, ICAM-1 is also upregulated during neuroinflammation and this 
upregulation can be detected using Gd-loaded liposomes decorated with anti-ICAM-1 mAb [94]. 
The upregulation of ICAM-1 in EAE was detected using MRI [94]. In the in vivo stroke animal 
model, MPIO decorated with anti-ICAM-1 (ICAM-1-MPIO) showed increased T2 signal in brain 
areas one hour after induction of transient middle cerebral artery occlusion (MCAO) [104]. 
Similarly, the same ICAM-1-MPIO detected the upregulation of ICAM-1 in the brain after 
radiation injury [105]. 
Neuroinflammation in the brain induces oxidative stress that is mediated by activation of 
myeloperoxidase (MPO) that is secreted by macrophages and monocytes [106]. MPO activation 
converts H2O2 into HOCl in the inflamed tissues, which can be used as biomarker for imaging of 
brain tissue at a molecular level. Because oligomerization of Gd-DOTA was previously shown to 
enhance MRI signal in tissues, Gd-bis-5-HT-DTPA (Figure 1.4) was designed to oligomerize and 
react with surrounding proteins in the brain tissue during activation of MPO in neuroinflammation 
process [106]. The activation of MPO in EAE mice was used for early detection of the disease. In 
this case, oxidation of 5-HT moiety on the probe induces probe reaction and oligomerization to 
surrounding proteins, which causes an increase in T1 relaxation time observed by MRI. This model 
can detect smaller active brain lesions better than Gd-DTPA alone in EAE mice [107]. Further, 
the enhanced MRI images were located at MPO-expressing cells and demyelinated areas in EAE 
mice. This method has the potential for early detection in patients with a presymptomatic stage of 
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MS. 
The oxidative stress process generates free radicals, which can be detected or trapped by 5,5-
dimethyl-1-pyrroline N-oxide (DMPO, Figure 1.4). An antibody to DMPO was conjugated to 
bovine serum albumin (BSA)-linked to Gd-DTPA-biotin to make a DMPO-mAb-BSA-Gd-DTPA-
biotin conjugate or anti-DMPO probe. After DMPO is delivered, it will react with membrane-
bound radicals (MBR) to produce DMPO-MBR in various tissues [108].  The DMOP-MBR can 
then be detected and localized by an anti-DMPO probe in a certain tissue as a measure of free 
radicals in the tissue. The localization and concentration of the anti-DMPO probe can be 
determined by MRI via detection of Gd-DTPA [108].  The localization of anti-DMPO using MRI 
can also be confirmed by delivering streptavidin-Cy3, which strongly binds to the biotin segment 
linked to DMPO probe. This method has been successful in detecting free radical formation in the 
lung, kidney, and liver of the streptozotocin-induced diabetic mouse model. Due to the large size 
of the DMPO probe, this method can only be used in tissues or organs outside of the brain. The 
use of this method to detect free radicals in the brain is only possible when restriction of large 
molecules through the BBB can be overcome. 
 
1.5.2. PET and SPEC Imaging: 
During tumor angiogenesis, αvβ3 integrins are upregulated on the vasculature endothelial cells. 
Cyclic arginine-glycine-aspartic acid (RGD) peptides have been developed to selectively bind αvβ3 
integrins; they have been investigated using diagnostic tools for tumor angiogenesis. Cyclic RGD 
peptides were conjugated with 18F-galacto for detection of αvβ3 upregulation using PET and 
SPECT, respectively, during angiogenesis in tumor growth in humans [109].  In human studies, 
18F-galacto-RGD as a detector of angiogenesis was compared to 18F-fluorodeoxyglucose (18F-
   31 
FDG, Figure 1.4) as a substrate to measure metabolism in primary and metastatic tumors. The 
images generated in tumors by both probes were observed by PET [109]. The results showed that 
detection with 18F-FDG was more sensitive than with 18F-galacto-RGD, suggesting that glucose 
metabolism was more pronounced than the increase in expression of αvβ3 integrins in the vascular 
endothelium during angiogenesis. Similarly, a 99mTc-labeled RGD peptide called 99mTc-NC100692 
has been used to detect upregulation of αvβ3 integrins in the vascular endothelium during 
angiogenesis. Although this radiotracer can detect breast cancer, the high uptake and clearance by 
the liver makes the use of this molecule inefficient for liver cancer diagnostic purposes. In addition 
to issues regarding the high clearance of the 99mTc-labeled RGD peptide, its use has not been 
explored for brain diseases due to its inability to cross the BBB. To improve the binding efficiency 
of RGD-derived radiotracers, multimeric cyclic RGD-peptides were developed. However, most 
studies of these multimeric RGD-peptides have only been carried out in vitro although, in general, 
the multimeric cyclic RGD radiotracers are more efficient than the monomeric cyclic RGD 
radiotracers [110].  
A translocator protein (TSPO) is upregulated in micro- and macroglia cells during 
neuroinflammation; thus, the upregulation of this  protein has been used as a diagnostic target of 
neurological diseases in rodents and humans [111]. The increase in expression of TSPO can be 
detected using 11C-PK11195 (Figure 1.4) as a ligand of TSPO, and the increased uptake of 11C-
PK11195 by glial cells in a stroke rat model compared to normal rats has been observed using 
PET. Similarly, the increase in deposition of 11C-PK11195 at the entorhinal, temporoparietal, and 
cingulate cortices of the brains of the transgenic Alzheimer’s disease mouse model were observed 
due to the   upregulation of TSPO. In addition, 11C-PK11195 can detect microglia activation in 
traumatic brain injury (TBI), stroke, and MS patients [112]. Brain lesions were detected using 
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localization of 11C-PK11195 in the brains of MS patients, and the detected lesions were similar to 
those identified using MRI. One of the disadvantages of in vivo detection of 11C-PK11195 is that 
the observed signal-to-noise ratio is poor due to high levels of non-specific binding of the ligand 
to non-targeted cells or tissues. In addition, 11C-PK11195 has a short in vivo half-life (i.e., 20 min). 
As an alternative, a higher selectivity ligand, 1C-DAA1106 (Figure 1.4), has been developed and 
evaluated in rodent models of Parkinson’s disease and TBI to overcome the poor signal-to-noise 
ratio of 11C-PK11195 [113]. 
Leukocyte trafficking into the brain can also be followed using SPECT. In this case, the 
leukocytes are labeled with 99mtechnetium (99mTc) or indium-111 (111I). However, 111I was found 
to be more toxic than 99mTc and can damage the leukocytes and their DNA [114]. The location of 
injected 99mTc-labeled leukocytes can be detected in the region of stroke damage in the brain using 
SPECT [115].  Similarly, PET/CT imaging with 18F-FDG has also been used to monitor the 
location of injected cells to detect neuroinflammation; unfortunately, the success in using 18F-FDG 
has been modest due to the short half-life of the radiolabel. Furthermore, 18F-FDG can be released 
from the target cell to cause images to have high background noise. 
Axon demyelination is a hallmark of MS, and early detection of demyelination in vivo is useful 
for MS patients to determine the course of treatment. Congo red has been shown to bind myelin, 
and 11C-labeled Congo red has been used for detecting demyelination using PET imaging [116]. 
The advantage of Congo red is that it can readily cross the BBB due to its favorable 
physicochemical to diffuse through the cellular membranes of the vascular endothelial cells of the 
BBB. This method is promising because it has been shown to detect the demyelination in the brains 
of baboons. However, due to the hydrophobic nature of Congo red, it has low water solubility; 
thus, 11C-CIC (Figure 1.4) was also developed to improve its solubility while it still can penetrate 
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the BBB to selectively bind to myelin rat brains to detect demyelination in EAE mice [117,118]. 
The ability to detect neuronal cell death can be very useful for early diagnosis of MS, 
Alzheimer’s, and Parkinson’s diseases because cell death is irreversible during the progression of 
these diseases.  11C-flumazenil (Figure 1.4) has been evaluated to detect neuronal lost in the brain 
of Alzheimer’s disease patients because 11C-flumazenil binds to GABAA receptors that are 
downregulated during neuronal damage in the brain [119]. Thus, the downregulation of GABAA 
receptors  can be detected by method 11C-flumazenil using PET. In early Alzheimer’s disease in 
patients, there is a decrease in 11C-flumazenil signals in several different parts of the brain 
including several cortical regions and posterior prediluvian regions. This method has also been 
used to determine neuronal damage in early stages of stroke [120].  
Neuronal cell death is correlated with the apoptotic process that expresses cell surface 
phosphatidylserine. Thus, 99mTC labeled annexin-V can be used to image the presence of 
phosphatidylserine on the surfaces of dead neuronal cells [121]. SPECT imaging has been used to 
detect 99mTC-labeled during fulminant hepatic cell apoptosis in a mouse model. In addition, 99mTc-
annexin-V can detect neuronal damage in ischemic stroke patients. In Alzheimer’s disease 
patients, the uptake of 99mTc-annexin-V in the cortex was increased; although the BBB normally 
does not allow such a large protein to penetrate, it is plausible that the brain uptake of annexin is 
due to the leakiness of the BBB [122-124].  Clinically, 99mTc-labeled annexin-V  has been used to 
detect cell death after organ rejection during transplantation [125].  
 
1.5.3. Near IR Fluorescence: 
Near IR fluorescence (NIRF) dyes have been used to detect molecules in the brain that cross 
the BBB as well as in detecting tumor angiogenesis and localization of tumors for surgery. NIRF 
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imaging can be done in vivo in a non-invasive manner because of low scattering, tissue absorption, 
and autofluorescence of tissues at 700–900 nm. Brain depositions of NIRF dyes and their 
conjugation to molecules (i.e., peptides, proteins, PEG) can be detected after their delivery using 
BBB modulator peptides to improve their penetration through the BBB [87,89]. The quantity of 
the delivered molecules in the brains can be conveniently determined by integrating the 
fluorescence intensity from the NIRF image.  
The NIRF tumor image from IR780 dye (Figure 1.4) has been used to determine the location 
and size of glioma tumors in the brain.  IR780 has low toxicity and high tumor targeting properties; 
however, it has low solubility that limits its preclinical and clinal applications [126]. To overcome 
the solubility problem, IR780 dye was formulated in liposome (IR780-liposomes, size 95 nm) and 
phospholipid micelle (IR780-micelles, size 26 nm) nanoparticles. It was found that the IR780-
micelles were more stable than IR780-liposomes. Using confocal microscopy, in vitro incubation 
of IR780-micelles in a glioma cell culture resulted in uptake and detection of micelles in the 
intracellular space of U87MG glioma cells [126].  IR780-micelles were also intravenously 
delivered via tail vein into mice with glioma brain tumors in which U87MG glioma cells were 
ectopically and orthotopically xenografted into the brains [126].  IR780-micelles were 
accumulated in orthotopic xenograft tumors and could be detected using NIRF imaging 4 days 
after delivery.  It was proposed that solid tumor accumulation of micelles was due to enhanced 
permeability and retention (EPR) effect of the micelle nanoparticles in the vasculatures. As a 
negative control, there was no observable NIRF image of micelles found in healthy mice. The 
tumor-specific targeting of IR780-micelles has been confirmed by ex vivo NIRF imaging of the 
brain [126]. 
NIR dyes have also been used to detect brain tumor xenografts using photoacoustic (PA) 
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imaging method with the goal of localizing tumors for surgery [127]. The PA image is produced 
by reconstructing collected acoustic waves from the NIR dye-conjugated nanoparticles that are 
excited by a laser beam penetrating deep into the tissue [127].  In general, PA detection of brain 
tumors using NIR-I wavelengths (650–980 nm) has a weak light signal due to the signal dampening 
by the skull. To overcome this problem, NIR-II-conjugate nanoparticles using P1 chromophore 
(Figure 1.4) were designed with an excitation of 1064 nm to avoid tissue suppression for better 
signal-to-noise ratio than with NIR-I. In this study, orthotopic xenografts of brain tumors were 
generated with luciferase-labelled U87 cells, and the presence, location, and size of the tumor was 
determined using MRI. Then, NIR-II nanoparticles were administered to the mice with brain 
tumor, followed by PA scanning. The results showed an increase in tumor detection with high 
background 1 h after administration; after 24 h, the image was observed exclusively from the 
tumor. There was 94-fold higher signal from the tumor than from the background before the 
administration of NIR-II-NP. 
 
1.6. Conclusion: 
The progress in diagnosing and treating brain diseases has been very slow because of the 
difficulty in delivering molecules non-invasively to the brain. Early diagnosis of brain diseases has 
been difficult, but it is important for halting the diseases in the early stage. Many advances have 
been made using small molecules to detect changes in the brain and to treat brain diseases. 
However, these advances are not occurring fast enough to overcome many problems in diagnosis 
and treatments of brain diseases. Many very selective and potent molecules such as peptides, 
proteins, carbohydrates, and oligonucleotides that can used for treatment of brain diseases have 
failed to advance in the clinic due to their inability to cross the BBB to exert their biological 
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activities in the brain. Thus, much effort should be devoted to improving the delivery of these 
molecules to the brain. Limited success has been achieved in delivering large molecules into the 
brain; however, the efficiencies of the methods used are lower than expected. The use of particles 
and exosomes for delivering diagnostics or therapeutics to the brain is still in the early stages and, 
due to the nature of the BBB, the use of particles for brain delivery could encounter an even higher 
barrier than that for delivering large molecules such as antibodies. Overall, there is a need to 
increase efforts in the brain delivery area to help in basic and applied sciences to solve brain disease 
problems as well as to study how the brain works at cellular levels. 
 
1.7. Tables, Figures, and Figure Legends:  
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Figure 1.1. (A) A cross-section diagram of the vascular endothelial cells of the BBB surrounded 
by pericytes, astrocytes, and neurons. Molecules that cross the BBB via transcellular- or 
paracellular-transport pathway are indicated by two different arrows. The presence of efflux pumps 
prevents some molecules to diffuse transcellularly across the membranes of the BBB. (B) A 
representation of the intercellular junction of microvessel endothelial cells of the BBB, which is 
composed of tight junction, adherens junction, and demosomes regions. The protein-protein 
interactions at the extracellular space act as “Velcro” to connect the membranes between opposing 
cells. The protein-protein interactions in the intercellular junctions are connected via cross-talk of 
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Figure 1.2. The formation of prodrug molecules   has been done to improve the delivery of drug 
molecules across the BBB. The formation of a prodrug changes the physicochemical properties to 
allow efficient partition into cell membranes for passive diffusion across the BBB. Ligand-
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the blood to the brain. The prodrugs are converted to the parent drug by enzymes such as esterase 




Figure 1.3. Cyclic prodrugs (1 and 3) from RGD-peptidomimetic (2) and Aggrastat (4) using 
(acyloxy)alkoxy and phenylpropionic acid promoieties, respectively. The cyclic prodrugs can be 
converted by clipping the ester bond by esterase to make the intermediate. The intermediates 
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Figure 1.4. Structures of molecules used in brain analysis including: (a) Gd-bis-5-HT-DTPA, (b) 
DMPO, (c) 18F-FDG, (d) 11C-PK11195, (e) 11C-DAA1106, (f) 11C-CIC, (g) 11C-Flumazenil, (h) 

























OCC2  GVNPQAQMSSGYYYSPLLAMC(Acm)SQAYGSTYLNQYIYHYC(Acm)TVDPQE;  






HAV6  Ac-SHAVSS-NH2 
ADTC5  Cyclo1,7(CDTPPVC) 
cIBR7 Cyclo1,8(CPRGGSVC) 
cLABL Cyclo1,12(PenITDGEATDSGC) 
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Chapter 2:  Non-Invasive Brain Delivery and Efficacy of BDNF to Stimulate 
Neuroregeneration and Suppression of Disease Relapse in EAE Mice 
1. Introduction: 
Brain diseases are difficult to diagnose and treat; thus, thousands of individuals suffer from 
brain diseases annually, including Alzheimer’s disease (AD), multiple sclerosis (MS), and brain 
tumors (e.g., glioblastoma, medulloblastoma). One of the primary reasons for this difficulty is the 
blood-brain barrier (BBB) that prevents functional molecules (e.g., drugs) and harmful toxins 
introduced into the bloodstream from entering the brain.1 To cross the BBB, a molecule must 
possess the appropriate physicochemical properties. Furthermore, efflux pumps and enzymes 
expel and metabolize molecules, respectively, preventing certain molecular species from crossing 
the BBB.  Because of the protective nature of the BBB, its selectivity imposes challenges for 
scientists to develop diagnostic and therapeutic agents for patients with brain diseases. This is 
especially apparent for modern biological drugs, such as monoclonal antibodies (mAbs), enzymes, 
and hormones. The physicochemical properties (i.e., size, charges, high hydrogen-bonding 
potentials, and hydrophilicity) of biologics prevent them from partitioning into the cell membranes 
of the BBB vascular endothelial cells and crossing through the cells (i.e., transcellularly).1  Due to 
their size, these molecules also cannot penetrate between the endothelial cells of the BBB (i.e., 
paracellularly) because the paracellular pathway’s tight junctions restrict the permeation of 
molecules with hydrodynamic radius larger than 11 angstroms (Å). 
Most available drugs for treatment of multiple sclerosis (MS) suppress only the immune 
response to halt the disease; for example, natalizumab (Tysabri®) is a monoclonal antibody (mAb) 
drug that prevents brain infiltration of activated immune cells that could damage the axon myelin 
sheath.2 Another widely prescribed treatment, glatiramer acetate (Copaxone®), has a mechanism 
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of action that is not entirely understood, but it is believed to ameliorate the disease by modulating 
Th1 to Th2 cells responses.3 Although these current drugs may halt MS disease progression, they 
do not reverse neuronal damage in the central nervous system (CNS). Although many researchers 
are currently investigating potential drugs for remyelination, no available drugs on the market can 
reverse damage of the myelin sheaths of neuronal axons. It has been shown previously that the 
extent of MS patient’s disability can be correlated to the levels of the axonal damage in the CNS;4 
therefore, a means to reverse axon demyelination could greatly improve MS patients’ quality of 
life.  
One way to reverse MS is to deliver molecules that can repair demyelination and/or neuronal 
damage to the CNS. Monoclonal antibodies (mAb) such as anti-Nogo-A,5 anti-LINGO-1,6 
sHIgM22,7 and VX15/25038 have been developed for inducing remyelination. Unfortunately, 
clinical trials for several of these mAbs, including anti-Nogo-A and anti-LINGO-1, have been 
terminated—anti-LINGO-1 mAb for lack of significant therapeutic efficacy, and anti-Nogo-A for 
reasons that have not been released. Alternatively, brain delivery of brain-derived neurotrophic 
factor (BDNF), 9, 10 nerve growth factor (NGF),11 and insulin-like growth factor 1 (IGF-1)12 has a 
potential benefit in reversing neurodegenerative diseases. BDNF stimulates neuron growth and 
remyelination in cell-culture systems and ex vivo brain slices and in vivo.9, 10 Direct delivery of 
BDNF via intracerebroventricular (ICV) injection to the lateral ventricle of brains of adult rats 
generates new neurons in the olfactory bulb, thalamus, hypothalamus, and parenchyma-striatum.13  
Remyelination in the brains of diseased animals allows the recovery of physical function, 
demonstrating a correlation between remyelination and recovery from disease symptoms in the 
EAE animal model.14, 15 While intravenous (I.V.) administration of neuroregenerative proteins 
(e.g., BDNF, NGF)  would be more practical, many attempts to deliver these proteins directly 
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across the BBB via the systemic circulation have not proven successful in inducing neuro-
regeneration/repair because they cannot cross the BBB.16 Therefore, there is an urgent need to 
develop effective and non-invasive trans-BBB delivery methods for supplying remyelinating 
neurotrophic factors into the brain.  
One alternative strategy to deliver drugs including proteins into the brain is via the paracellular 
pathway (i.e., intercellular junctions) of the BBB. In this case, modulation of intercellular junctions 
of the BBB can increase the paracellular pathways of the BBB. The osmotic method of using a 
hypertonic mannitol solution has been successful in modulating intercellular junctions.17 The 
hypertonic solution shrinks the BBB endothelial cells to increase the porosity of the paracellular 
pathway and allows anticancer drugs, including mAbs, to cross the BBB to treat brain tumors.17 
Alternatively, our group has investigated a new approach to modulating the BBB using cadherin 
peptides. In this case, cadherin peptides were designed inhibit cadherin–cadherin interactions in 
an equilibrium and dynamic fashion to increase the porosity of the paracellular pathway.1, 18 In 
healthy animals, in vivo, cadherin peptides (e.g., HAV6: Ac-SHAVSS-NH2 and ADTC5: 
Cyclo(1,7)Ac-CDTPPVC-NH2) have been shown to deliver small molecules, peptides, and 
proteins (e.g., galbumin) to the brain by modulating the BBB for a very short period of time.19-22 
Recently, HAV6 and ADTC5 peptides have been shown to deliver various sizes of protein (i.e., 
15 kDa lysozyme, 65 kDa albumin, 150 kDa IgG mAb) into the brain of healthy C57BL/6 mice 
when both BBB modulator and protein were delivered via I.V. administration.23 Secondly, Novel 
cyclic HAV and ADT peptides have been designed to improve the BBB modulatory activity to 
deliver IgG mAb into the brain of C57BL/6 mice.24 Thirdly, a combination of HAV6 and an 
anticancer drug, adenanthin, was effective in suppressing medulloblastoma brain tumor growth 
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and increasing survival rate of the mice.25 Finally, HAV6 peptide improved oral absorption and 
brain delivery of eflornithine by improving its paracellular permeation.26 
In this study, BDNF (13 kDa monomer) was delivered to the brains of relapsing-remitting 
experimental autoimmune encephalomyelitis (RR-EAE) mice using ADTC5 peptide via I.V. 
administrations to induce remyelination and neurorepair as a less invasive method compared to 
ICV.13 Four different groups of EAE mice were treated eight times with BDNF+ADTC5, BDNF 
alone, ADTC5 alone or vehicle during the remission period of EAE. Therapeutic effects of 
delivering BDNF in vivo were evaluated by observing the amelioration of EAE relapse and 
comparing clinical body scores across treatment groups. Finally, the effects of BDNF in the brains 
of EAE mice were evaluated using several ex vivo analyses to indicate remyelination and the 
degree of NG2-glia activity as well as by probing mRNA transcript upregulation of proteins 
affected by BDNF. 
 
2.2. Materials and Methods: 
2.2.1 Animals: 
The protocols to use live mice have been approved by the Institutional Animal Care and Use 
Committee (IACUC) at The University of Kansas. SJL/elite mice were purchased from Charles 
River Laboratories, Inc. (Wilmington, MA). All mice were housed under specific pathogen-free 
conditions at the animal facility at The University of Kansas approved by the university Animal 
Care Unit (ACU). The animals were maintained in the Animal Care Unit with free access to food, 
water, and rotating stimuli. 
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2.2.2. Cadherin Peptide Synthesis and Purification: 
The syntheses of the ADTC5 and PLP139-151 peptides were accomplished using a solid-phase 
peptide synthesizer (Gyros Protein Technologies, Tucson, AZ). After peptide cleavage from the 
resin using TFA, the crude peptides were precipitated overnight in cold diethyl ether. In most 
cases, the crude precipitate showed high concentrations of the desired peptide. The formation of a 
disulfide bond in the cyclic peptide (i.e., ADTC5) was accomplished by vigorously stirring the 
precursor linear peptide in bicarbonate buffer solution under air oxidation at pH 9.0 in high 
dilution. The cyclization reaction produced primarily the desired monomer with minor oligomer 
side products; the monomer peptide was isolated from the mixture using a semi-preparative HPLC 
X-bridge C18 column (Waters, Milford, MA).  After purification with semi-preparative HPLC, 
the isolated peptides had high purity (> 95%) as determined by analytical HPLC. The exact mass 
of each peptide was determined by mass spectrometry. 
 
2.2.3. EAE Mouse Model: 
EAE disease in animals (5−8-week-old SJL/elite female mice, Charles River) was stimulated 
by injecting 200 μg of PLP139−151 peptide in a 0.2 mL emulsion containing equal volumes of PBS 
and complete Freund’s adjuvant (CFA) with killed mycobacterium tuberculosis strain H37RA 
(Difco, Detroit, MI; final concentration 4 mg/mL) as described previously.27, 28 Briefly, 50 μL of 
PLP/CFA emulsion was administered to four different regions above the shoulders and the flanks 
on Day 0 followed by intraperitoneal injection of 200 ng of pertussis toxin (List Biological 
Laboratories, Campbell, CA) on Days 0 and 2. Clinical scores that reflect the disease progression 
were determined using an 11-point scale with 0.5 increments ranging from 0 to 5; 0 being no 
apparent disease and 5 being moribund. On Day 21, mice were randomly separated into 3 treatment 
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groups: (i) BDNF (5.7 nmol/kg) + ADTC5 (10 µmol/kg; n = 7), (ii) BDNF alone (5.71 nmol/kg, 
n = 6), (iii) ADTC5 alone (10 µmol/kg; n = 5), and (iv) vehicle (n = 5). All mice received 8 
intravenous injections every 4 days beginning on Day 21. The mice were euthanized via CO2 
inhalation on Day 55. Area under the curve (AUC) calculations were used to compare clinical 
scores across groups; AUC calculations were performed using the trapezoid rule from Days 21 to 
55. 
 
2.2.4. Euthanasia, Brain Perfusion, and Extraction:  
All mice were euthanized via a CO2 chamber. Immediately following euthanasia, mice 
underwent cervical dislocation and were transcardially perfused with PBS + 0.2% Tween-20 
followed by perfusion-fixation with a 4% paraformaldehyde and 30% sucrose PBS solution. 




Fixed brain samples were submitted to IHC World (Ellicott City, MD) for paraffin embedding, 
tissue sectioning (5 μm), anti-NG2 (Abcam, Cambridge, UK) staining via DAB, and Luxol-fast 
blue staining. Staining protocols described on the IHC World website for Luxol-fast blue and 
immunohistochemistry enzyme HRP were performed. For both procedures, brains were cut into 5 
µm sections and then deparaffinized and rehydrated using xylenes and an ethanol-water gradient. 
For Luxol staining, sections were incubated in Luxol-fast blue solution at 56 ºC overnight and 
subsequently rinsed with 95% ethyl alcohol followed by distilled water. For anti-NG2 mAb 
staining, sections underwent antigen retrieval, followed by rinsing with PBS-Tween 20 for 2 x 2 
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minutes. Sections were incubated with normal serum block followed by primary antibody 
incubation with anti-NG2 mAb at 4 ºC overnight and subsequently rinsed with PBS-Tween 20. 
Sections were then blocked using a peroxidase blocking solution for 10 min at room temperature 
(RT). Next, samples were incubated with a biotinylated secondary antibody at 1–10,000 dilution 
in PBS for 30 min at RT. Sections were then incubated in streptavidin-HRP in PBS for 30 min at 
RT followed by incubation in DAB solution for 1–3 min. Sections were dehydrated through 95% 
ethanol for 2 min, 100% ethanol for 2 x 3 min, and cleared with xylene. Sections were mounted 
using aqueous mounting media and coverslipped using 1.5 coverslips. 
Luxol-fast blue and anti-NG2 mAb images were taken under identical conditions on a Zeiss 
Axioplan 2 microscope (Oberkochen, Germany) equipped with a mercury lamp excitation source, 
and 40X (Luxol) and 20X (anti-NG2) air objective lenses. Greyscale images for quantification 
were taken using a 1344 x 1024 Orca ER CCD camera (Hamamatsu Photonics, Japan), color 
images for qualitative purposes were taken using a 1.3 MP Spot Color camera (Spot Imaging, 
Sterling Heights, MI). To determine the degree of demyelination (i.e., breakages in the myelin 
sheath), 5 greyscale images from each group were randomly selected and converted to binary, and 
regions of interest (ROI) were manually selected within the lateral corpus callosum using ImageJ 
(National Institute of Health, Bethesda, MD). A binary value of ‘1’ (i.e., white signal) implied a 
lack of myelin, whereas a binary value of ‘0’ (i.e., black signal) implied myelin. The mean value 
of each ROI from each image was recorded. To determine the degree of anti-NG2 staining, 
densitometry analysis was performed on DAB stained sections; greyscale images were taken under 
equal exposure times and 5 images per group were randomly selected and used for analysis. ROIs 
of identical size were selected within the medial corpus callosum. The integrated mean grey value 
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for each ROI from each image was recorded. Staining background was controlled for by subtracted 
an aggregate of mean grey values from 5 ROIs of negative controls from each group.  
 
2.2.6. Fluorescent In Situ Hybridization: 
Coronal brain sections (5 μm thickness) from mid- and hind-brain were sectioned and washed 
three times in PBS before mounting on gelatin-coated glass slides (Superfrost Plus, Thermo Fisher 
Scientific). Tissue was allowed to dry at RT and then stored at –20 ºC until use. Fluorescent in situ 
hybridization (FISH) was performed using RNAscope® Technology 2.0, Advanced Cell 
Diagnostics (ACD), Hayward, CA) Multiplex Reagent Kit V2.29-31 In short, mounted tissue 
sections were deparaffinized using xylene and serially dehydrated in 50%, 70%, 95%, and 100% 
ethanol for 5 min each. In between all pretreatment steps, tissue sections were briefly washed with 
nanopure water. Pretreatment solution 1 (hydrogen peroxide reagent) was applied for 10 min at 
RT and then the tissue sections were boiled in pretreatment solution 2 (target retrieval reagent) for 
15 min. Mounted slices were pretreated with solution 3 (protease reagent) for 30 min at 40 ºC in 
the HybEz™ hybridization system (ACD). Following tissue pretreatment, the following transcript 
probes were applied to all sections: Mm-EGR1-C1 (Cat. # 423371), Mm-NOS1-C2 (Cat. # 
437651-C2), and Mm-ARC-C3 (Cat. # 316911-C3), which correspond to early growth response 1 
(EGR1), nitric oxide synthase 1 (NOS1), and activity-related cytoskeleton-associated protein 
(ARC). Probes were hybridized to sections for 2 hours (h) at 40 ºC and then subsequently washed 
for 2 min at room temperature. Following hybridization, hybridize AMP 1 was applied to each 
slide, which was then incubated for 30 min at 40 ºC. The same process was repeated for hybridize 
AMP 2 and 3. For HRP-C1 signal development (EGR1), HRP-C1 was applied to each slide, which 
was incubated for 15 min at 40 ºC and then washed. For C1, TSA® Plus fluorescein (Perkin Elmer, 
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Akron, OH) was applied and incubated for 30 min at 40 ºC and then washed. Following the wash, 
HRP blocker was applied to each slide, which was incubated for 15 min at 40 ºC and then washed. 
This process was repeated for C2 (NOS1), and C3 (EGR1) using TSA® Plus Cy3 and Cy5, 
respectively. The resulting transcript-fluorophore labeling is as follows: EGR1-fluorescein, 
NOS1-Cy3, EGR1-Cy5. All sections were counterstained by incubating DAPI for 30 seconds (sec) 
at RT following by rinsing. Slides were then covered using ProLong Gold Antifade Mountant and 
1.5 coverslips. Slides were allowed to dry in the dark overnight at 4 ºC. All sections were imaged 
within 2 weeks. 
Fluorescent images were taken using an Olympus Inverted Epifluorescence Microscope XI81 
(Olympus Life Solutions, Waltham, MA) running SlideBook Version 5.5 (3i, Ringsby, CT) 
equipped with a digital CMOS camera (2000x2000), automatic XYZ stage position, ZDC 
autofocus, and a xenon lamp excitation source. Images were taken using a 20X objective and 
appropriate filter sets for each fluorophore (i.e., DAPI, FITC, Cy3, C5). To determine the degree 
of mRNA transcript expression, 5 images of analogous regions of the cerebral cortex were 
randomly selected from mouse samples of each group, and the total number of cells expressing 
each mRNA transcript were counted using ImageJ. The number of cells expressing each mRNA 
transcript was normalized against the total number of cells (as determined by DAPI) to ensure that 
analyzed areas had equal cell density. For display purposes, images were pseudo colored using 
ImageJ; green was assigned to fluorescein (EGR1), magenta was assigned to Cy5 (ARC), and blue 
to DAPI.  NOS images were not incorporated due to virtually no signal detection. 
 
2.2.7. Western Blots:  
Female SJL/elite mice, 5 weeks of age (Charles River) were initially intravenously injected via 
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lateral tail vein with 5.71 nmol/kg BDNF (Peprotech, Rocky Hill, NJ) with (n = 3) or without (n 
=3) 10 µmol/kg ADTC5. BDNF was allowed to circulate for 20–30 min prior to euthanasia via 
CO2. Immediately following euthanasia, mice were transcardially perfused with protease inhibitor 
infused TRIS buffer (pH 7.4). The brains of the mice were extracted and placed in the perfusate 
buffer on ice. For Western blotting, 100–150 mg of brain tissue was sectioned from the most 
ventro-posterior portion of the brain and placed in 200–250 μL of solution mixture containing 66% 
tissue protein extraction reagent (TPER; Thermo Fisher, Waltham, WA) and 33% 50 μL of neural 
protein extraction reagent (NPER; Thermo Fisher) with protease and phosphatase inhibitors 
(Thermo Fisher). The tissue samples were lysed via sonication using a Sonic Disembrator 500 
(Thermo Fisher) at an amplitude level of 15 Hz for a maximum of 10 sec. Following sonication, 
the samples were vortexed for one minute and then centrifuged at 4 ºC and 13,000 RPM for 30 
min. The sonication, vortexing, and centrifugation were repeated 2 times. Following lysis and 
centrifugation, NuPAGE™ 4–12% Bis-Tris Protein Gels (1.5 mm, 10-well, Thermo Fisher) were 
loaded with 60 μg of protein and Licor (Lincoln, NE) loading buffer. A BDNF standard of less 
than 1.0 μg was also loaded for positive control. The gel was run at 100 V for 2 h. Following the 
gel, the protein bands were transferred to a nitrocellulose membrane (Licor) at 36 V overnight. 
Following the transfer, the membrane was stained with REVERT (Licor) for 3 min and then 
washed using the REVERT Wash Solution for 2 min followed immediately by scanning using a 
Licor Odyssey at 700 nm. Next, the membrane was washed using the REVERT Reversal Solution 
(Licor) and subsequently blocked for 2 h at 4 ºC using Licor TBS blocking reagent. The membrane 
was then incubated with the primary antibody, anti-BDNF (Abcam), at a 1:1,000 ratio in TBS + 
0.1% Tween-20 for 36 h at 4 ºC. Following primary antibody, the membrane was rinsed and 
incubated with the IR800-conjugated secondary antibody (Licor) for 1.5 h at room temperature in 
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the dark. The membrane was then immediately scanned using a Licor Odyssey CLX at a 
wavelength of 800 nm. Following imaging of BDNF bands on the membrane, the membrane was 
stripped using stripping buffer to be reprobed for the phosphorylated-TrkB (pTrkB) receptor with 
anti-phospho-TrkB (EMD Millipore, Burlington, MA) at a 1:1,000 dilution in TBS + 0.1% Tween-
20 for 24 h at 4 ºC. Following primary antibody incubation, the membrane was rinsed and 
incubated with the IR800-conjugated secondary antibody for 1.5 h at room temperature in the dark. 
The membrane was then immediately scanned using the same parameters as for the BDNF 
imaging. These bands were not densiometrically analyzed due to high background signal; 
however, they are shown for qualitative analysis. 
To improve the level of detection of BDNF and pTrkB bands via Western blot, the above 
process was repeated with an increase in dosages of BDNF. The dosages of ADTC5 remained 
constant; mice received either  57.1 nmol/kg BDNF (10-fold increase) + 10 µmol/kg ADTC5 (n = 
2), 28.6 nmol/kg  BDNF (5-fold increase) + 10 µmol/kg ADTC5 (n = 1), or 28.6 nmol/kg BDNF 
alone (5-fold increase; n = 3). These images were not quantified due to the variation in dosing 
regiments; however, they are provided for qualitative analysis of BDNF brain depositions. 
 
2.2.8. Statistics: 
All statistics were performed using GraphPad Prism (San Diego, CA). Analysis of variance 
(ANOVA) and Student’s T-test were performed when appropriate, both operating at 95% 
confidence intervals with a p-value of less than 0.05 used as the criterion for statistical significance 
unless otherwise stated.  
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2.3. Results: 
2.3.1 Effect of BDNF Brain Delivery by ADTC5 on Suppression of EAE Relapse: 
The ability of ADTC5 to deliver BDNF into the brains of mice after I.V. administrations was 
assessed by determining the effects of BDNF in suppressing disease relapse in the relapsing-
remitting EAE animal model. The efficacy of BDNF (5.71 nmol/kg) + ADTC5 (10 µmol/kg; n = 
7) was compared to that of BDNF alone (5.71 nmol/kg; n = 6), ADTC5 alone (10 µmol/kg; n = 5), 
and vehicle (n = 5). I.V. injections were performed every 4 days up to eight injections starting 
from day 21 during the time of disease remission and relapse. EAE clinical scores were monitored 
daily from the beginning to the end of the study. The EAE mice that received injections of BDNF 
+ ADTC5 had clinical body scores significantly lower over time compared to the mice that 
received BDNF alone, ADTC5 alone or vehicle (Figure 2.1A). The mice that received injections 
of BDNF + ADTC5 showed normal locomotion on all four limbs, with some residual tail paralysis. 
In contrast, mice that received BDNF alone, ADTC5 alone or vehicle showed partial or full hind 
leg paralysis and full tail paralysis. 
The differences in clinical body scores were distinguished by generation of the areas under the 
curve (AUC) disease scores of all four groups from day 21 to day 55, after the peak of the disease. 
It was found that mice that received injections of BDNF + ADTC5 had significantly lower ACU 
disease scores compared to those that received BDNF alone, ADTC5 alone or vehicle (F(3,19) = 
3.180; p ≤ 0.05; Figure 2.1B). There was no significant difference in the clinical scores between 
treatments with BDNF alone, ADTC5 alone and PBS (F(2,13) = 0.128; p = 0.881). The results 
suggest that ADTC5 helps BDNF to penetrate the BBB to exert its biological activity in the brain 
while BDNF alone did not have efficacy due to its inability to penetrate the BBB. Further 
   74 
evaluation of the therapeutic efficacy of systemically delivered BDNF using ADTC5 peptide was 
assessed using histological, immunohistochemical, and hybridization methods.  
 
2.3.2. Effect of BDNF on Remyelination: 
The ability of BDNF to induce remyelination has been previously demonstrated using BDNF 
knockout mice in which myelin loss was shown to be sensitive to a lack of BDNF expression.32 
Additionally, BDNF has been shown to improve remyelination and regeneration of nerve fibers 
after C7 ventral root avulsion and replantation.33 Thus, we probed myelin levels in the brains of 
mice as an indication that BDNF is successfully entering the CNS and exerting an effect. Myelin 
levels in the brain were imaged using Luxol fast-blue chromogen staining. Figure 2.2A shows 
noticeably more dense myelin staining in the lateral corpus callosum in mice that received BDNF 
+ ADTC5 (n = 5) compared to those that received BDNF alone (n = 5), or vehicle (n = 5). The 
mice that received BDNF alone or vehicle showed myelin discontinuity (white spaces) in the 
corpus callosum. Quantification via densitometry using binary images of myelin staining showed 
a statistically significant increase in myelin density in the lateral corpus for mice that received 
BDNF+ADTC5 compared to those that received BDNF alone or vehicle (F(2,12) = 21.72; p ≤ .001) 
Figure 2.2B). This result supports the idea that BDNF successfully entered the brain with the help 
of ADTC5 and induced remyelination in the corpus callosum. 
 
2.3.3. Effect of BDNF on NG2-Glia: 
The NG2 receptors have previously been shown to facilitate the maturation of oligodendrocyte 
precursor cells and have been demonstrated to be distinctly upregulated in BDNF+/+ mice 
following the development of cuprizone-induced lesions.32, 34 We further probed NG2 receptor 
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presence as an additional indicator that BDNF is indeed entering the CNS and exerting a 
therapeutic effect. NG2 receptor levels were quantified using anti-NG2 immunohistochemistry 
staining. A higher degree of NG2 staining in the medial corpus callosum of mice was found in 
animals that received BDNF + ADTC5 (n = 5) compared to those that received BDNF alone (n = 
5) or vehicle (n = 5; Figure 2.3A). Quantification of the degree of NG2 staining was determined 
using mean grey values. Mice that received BDNF + ADTC5 showed a significantly increased 
level of anti-NG2 staining compared to those that received BDNF alone or vehicle (F(2,12) = 10.44, 
p ≤ 0.01; Figure 2.3B). These results are evidence that BDNF is inducing oligodendrocyte 
maturation and, in turn, remyelination. 
 
2.3.4. Effects of BDNF on EGR1, ARC, and NOS1 mRNA Transcript Expression: 
BDNF exposure is well known to affect downstream transcription factors including c-fos, 
cAMP response element binding protein (CREB), early growth response-1 (EGR-1), and EGR3.35, 
36 Furthermore, EGR1 has been demonstrated to target the activity-regulated ARC gene, and EGR1 
is also upregulated by BDNF exposure.37, 38 In addition, BDNF has not only been shown to 
upregulate specific downstream transcripts, but has also been shown to inhibit the expression of 
nitric oxide synthase 1 (NOS1).39 Therefore, we probed three mRNA transcripts, EGR1, ARC, and 
NOS1 for evidence that BDNF is entering the brain and exhibiting effects. The mRNA expression 
levels of EGR1, ARC, and NOS1 mRNA were quantified using fluorescent in situ hybridization 
(FISH). Figures 2.4A and 2.4B show brain sections from the mid and hind brain, respectively; 
mice that received BDNF + ADTC5 have noticeable upregulation of EGR1 and ARC mRNA 
transcripts compared to mice that received BDNF alone or vehicle.  However, images for the NOS1 
mRNA expressions are not shown due to low level of detectability. The mRNA expression levels 
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were quantified using cell counting that was normalized against the number of cell nuclei to ensure 
that analyzed areas were of equal cell density. Composite images of all fluorescent channels 
showed a pronounced increase in mRNA transcripts that can be seen for the mice that received 
BDNF + ADTC5 (n = 5) compared to the mice that received BDNF alone (n = 5) or vehicle (n = 
5; Figures 2.4A, B). Figure 2.4C shows a significant increase in EGR1 (F (2,12) = 47.10; p ≤ 0.001) 
and ARC (F (2,12) = 33.43; p ≤ 0.001) expression levels for mice that received BDNF+ADTC5 
compared to those of the mice that received BDNF alone or vehicle. In contrast, there was no 
significant difference in NOS (F (2,12) = 1.826; p = 0.203) or DAPI (F (2,12) = 0.504; p = 0.617) 
staining across the three groups (Figure 2.4D).  
 
2.3.5. Detection of BDNF in the Brain using Western Blots: 
The ability of ADTC5 to deliver BDNF into the brain was confirmed by Western blot analysis 
of the brain homogenates. To determine if BDNF entered the brain using the ADTC5 peptide, mice 
were initially given a 5.71 nmol/kg BDNF injection with (n = 3) or without (n = 3) 10 µmol/kg 
ADTC5 and were sacrificed after 20 minutes to allow for sufficient circulation and activation of 
the pTrkB pathway. Figure 2.5A shows a notable increase in detection of BDNF bands in the 
brains of mice that received injections of BDNF + ADTC5 compared to those that received BDNF 
alone, where delivered BDNF was undetected. Because of high background, pTrkB could not be 
detected with confidence using this Western blot. 
Due to suboptimal detection of pTrkB using 5.71 nmol/kg BDNF injections, the above process 
was repeated with increases in dosage of BDNF to 57.1 nmol/kg but with the dosages of ADTC5 
remaining constant. Mice received either 57.1 μmol/kg BDNF (10-fold increase) + 10 µmol/kg 
ADTC5 (n = 2), 28.6 nmol/kg BDNF (5-fold increase) + 10 µmol/kg ADTC5 (n = 1), or 28.6 
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nmol/kg BDNF alone (5-fold increase; n = 3). Figure 2.5B more clearly shows an increase in 
detection of BDNF and pTrkB bands for mice that were treated with BDNF + ADTC5 compared 
to mice that were treated with BDNF alone. Additionally, to ensure that total protein loaded into 
each well across all groups was consistent, a total protein stain was performed (Figure 2.5C); this 
serves as a more reliable and accurate loading control in comparison to detecting a ubiquitous 
protein such as actin. There was no significant difference in the total protein loading across each 
group (t (4) = 1.808; p = 0.145). Due to the variation of dosages of BDNF administered, the 
densiometric BDNF and pTrkB bands cannot be statistically compared with confidence; however, 
the relative intensities are shown in Figure 2.5D.  The aggregate results of these two Western blots 
indicate that BDNF is successfully entering the CNS and inducing an immediate effect on 
upregulation of pTrkB.  
 
2.4. Discussion 
Here, we have demonstrated that multiple injections of BDNF using ADTC5 peptide during 
the remission period of the relapsing-remitting EAE mice suppressed the disease relapse compared 
to treatment with BDNF alone, ADTC5 alone or vehicle. The selection of BDNF in this study 
because it is an endogenous molecule; thus, its delivery may not cause an adverse side effects in 
EAE mice. There is a significant improvement of the disease clinical scores during remission when 
the EAE mice were treated with BDNF+ADTC5 compared to those treated with BDNF alone, 
ADTC5 alone, and vehicle (Figures 2.1A-B).  A combination of BDNF + ADTC5 induced 
remyelination of the axons to reverse the neuronal damage caused by the immune cells (Figures 
2A-B). As expected, administering BDNF alone, ADTC5 alone, or vehicle did not have any effect 
on suppressing the disease relapse. BDNF alone did not induce remyelination because BDNF alone 
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could not penetrate the BBB. In addition, ADTC5 alone has no inherent neuroregenerative 
properties. The suppression of disease symptoms in the treatment group with BDNF + ADTC5 
indirectly suggests that ADTC5 helps to deliver BDNF into the brain (Figure 2.1).  
Our previous study showed that the effect of ADTC5 alone on the integrity the BBB 
intercellular junctions in vivo was reversible in healthy mice. Using transmission electron 
microscopy (TEM), evaluation of the BBB endothelial microvessels 2-h after treatment with 
ADTC5 showed the morphology of the endothelial cells were similar to those of in vehicle-treated 
mice.20 ADTC5-treated mice have no change in appearance of the brain capillaries and their tight 
junctions have normal ultrastructural characteristics. The vehicular activity in the vascular 
endothelial cells appears normal 2-h after ADTC5 treatment. In a parallel study, in vivo modulation 
of the BBB using a cadherin peptide, HAV6 peptide, in mice did not upregulate ionized calcium 
binding adaptor molecule 1 (Iba1), which is a marker for microglia activation and glial fibrillary 
acidic protein (GFAP), which is a marker of astrogliosis. This suggests that cadherin peptides may 
not induce neuroinflammation. This is different than the effects of osmotic BBB modulation which 
shows altered morphology and disruption of the tight junction ultrastructure as well as potential 
astrogliosis.40-42 The opening of the intercellular junctions by ADTC5 has a limited  time duration. 
In this case, the duration of BBB opening for small molecules like Gd-DTPA is between 2–4 h 
while for a large molecule like 65 kDa galbumin is between 10–40 min. A more important question 
is what is the effects of repeated treatment with ADTC5 on the BBB, animal behavior and toxicities 
to the brain and other organs in healthy and diseased animals. This study is currently planned to 
evaluate the potential side effects of cadherin peptides. 
As direct evidence that ADTC5 can deliver BDNF into the brain, unlabeled BDNF was 
delivered with and without ADTC5. After delivery, Western blots showed that recombinant BDNF 
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was detected in brain homogenates from mice treated with BDNF + ADTC5 compared to no 
detection of recombinant BDNF for mice that received BDNF without ADTC5 (Figures 2.5B-C). 
Qualitatively, the increase in BDNF doses in BDNF + ADTC5-treated mice shows increases in 
the amounts of detected BDNF in the brain homogenates in Western blots.  In addition, the increase 
in BDNF doses upregulates the pTrkB receptor expression (Figures 2.5B-C).43, 44 This is a first 
proof-of-concept for preclinical demonstration that ADTC5 can deliver BDNF into the brain after 
I.V. administrations to suppress EAE disease relapse in the mouse model.  
Demyelination is a hallmark trait of multiple sclerosis as well as in cuprizone and EAE mouse 
models.  Reduced myelin levels in the corpus callosum in humans and both animal models are 
commonly observed.45, 46 In our case, mice treated with BDNF + ADTC5 showed a significant 
increase in both myelin density as determined by Luxol fast blue (Figures 2.2A-B) and NG2 
presence in the corpus callosum, as indicated by immunohistochemistry staining (Figures 2.3A-
B) compared to mice that received BDNF alone or vehicle. These data are consistent with those 
from previous studies indicating that BDNF plays an integral role in remyelination and NG2 
upregulation.34, 47, 48 
Neurotrophins such as NGF, BDNF, neurotrophin-3,4/5 (NT3, NT4/5), and IGF1 have been 
known to regulate the viability, development, and function of neurons. However, BDNF has been 
by far the most studied to reveal its role in brain health.49 A decrease in BDNF levels in vivo in 
BDNF+/- mice reduces the number of NG2+ cells and myelin levels throughout the development, 
suggesting a correlation between NG2 cells and remyelination.34, 47, 48 In the cuprizone animal 
model used for studying remyelination, the demyelination in the corpus callosum is correlated with 
the decrease in BDNF, suggesting a relationship between BDNF levels in the brain and 
demyelination. A cuprizone mouse model shows demyelination after 4- and 5-week treatments 
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with cuprizone. Administration of cuprizone to BDNF+/+ mice exhibited a counter response by 
increasing remyelination of NG2 cells as indicated by upregulation of NG2 receptors. However, 
this increase in NG2 receptors in cuprizone-treated BDNF+/+ mice was significantly lower than 
those in untreated of BDNF+/+ mice. The results indicate that BDNF has an integral role in the 
proliferation of NG2 cells and the remyelination process.32, 34   
To further evaluate the effects of BDNF brain delivery in EAE mice, upregulations of several 
BDNF-stimulated mRNAs were determined for those that delivered the information from the gene 
to protein expressions.  BDNF is known to activate signaling pathways for rapidly modifying the 
function of local targets (e.g., phosphorylating TrkB); it also has a long-term effect on gene 
transcription (e.g., CREB,  EGR1 upregulation, ARC synthesis).35 In this study, BDNF has been 
shown to stimulate phosphorylation of TrkB in normal mice (Figure 2.5C). The brain slices from 
BDNF+ADTC5-treated EAE mice exhibited a significant increase in activity-regulated 
cytoskeletal-related (ARC) and early growth response-1 (EGR1) transcripts (Figure 2.4) 
compared to those of controls treated with BDNF alone or vehicle. Thus, this indicates that BDNF 
enters the brain with the help of ADTC5 to exude its biological activity to stimulate  ARC and  
EGR1 mRNA upregulations.36, 50, 51 BDNF has been demonstrated to upregulate ARC in cell 
cultures, and transcription of the ARC gene is essential for late-phase, long-term potentiation in 
the cortex.36, 51  In addition, EGR1 and EGR3 have been shown to directly regulate  ARC 
synthesis.37  EGR1- or EGR3-deficient mice lack ARC protein in some neurons; however, when 
the mice are deficient in both EGR1 and EGR3, all the neurons lack ARC protein. In this study, 
upregulation of EGR1 and ARC mRNAs was presumably due to delivered BDNF in the brain 
(Figures 2.4A-C).  
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Nitric oxide synthase 1 (NOS1) mRNA was also probed; however, no significant change in 
the NOS1 mRNA was observed by comparing brain slices for all three groups, indicating no effect 
of BDNF on NOS1 mRNA. It has been shown that the increase in BDNF mRNA is dependent on 
the increase in NOS1 mRNA upon exercise because NOS1 mRNA stimulates BDNF increase in 
the hippocampus during exercise as well as in the mouse brain after stroke.52   The lack of NOS1 
notable expression may be because BDNF does not use the nitric oxide pathway as other 
neurotrophins (e.g., NGF, IGF1) do.53 Additionally, BDNF has been shown to block NOS 
expression in rats to achieve BDNF homeostasis levels in the brain.39   
Many researchers have also investigated different ways for non-invasive brain delivery of 
BDNF. One of these is via transcytosis across the BBB using receptor-mediated transport; in this 
case, BDNF is conjugated to OX26 monoclonal antibody (mAb), which is a transferrin receptor 
(TfR) mAb.54, 55 This method has been referred to as the “Trojan horse” method, and the conjugate 
has been shown to cross the BBB in an animal model. Unfortunately, this transcytosis process may 
not be very efficient for carrying sufficient amounts of BDNF into the brain. There are several 
potential reasons for the inefficiency of this transcytosis method. First, due to the tight binding of 
mAb to TfR, a higher percentage of the conjugate is degraded in lysosomes of the BBB 
microvessel endothelial cells; thus, a lower amount of the delivered conjugate undergoes 
transcytosis into the brain side of the microvessels. Second, when the conjugate is transported into 
the brain side of the vascular endothelium, the conjugate cannot be released from TfR into the 
brain due to the very high affinity of the mAb to the TfR. As a result, the conjugate cannot 
effectively diffuse into brain tissues where BDNF is needed. Finally, conjugation to the mAb 
moiety could lower the BDNF binding affinity to the BDNF receptor, resulting in lower in vivo 
efficacy. Another BDNF delivery method across the BBB utilizes ultrasound along with 
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microbubbles; however, this method has not been applied to deliver BDNF in animal models of 
disease.56-58 Ultrasound methods have been regarded as safe and reversible based upon a short-
term histological assessment; however, the risks associated with recurrent and frequent uses of 
ultrasound have not been fully determined.59, 60  
Our previous studies have shown that ADTC5 enhanced brain delivery of 65 kDa galbumin 
into the brains of living mice as detected using magnetic resonance imaging (MRI) imaging.22 
Galbumin distributions were found throughout the posterior, mid-brain, and anterior regions of the 
brain with the highest deposition at the posterior followed by mid-brain and finally the lowest 
deposition in the anterior region. Recently, ADTC5 has been shown to deliver various size proteins 
into the brain of healthy mice, including IRdye800CW-labeled 15 kDa lysozyme, 60 kDa albumin, 
and 150 kDa IgG mAb.23 As in galbumin, with NIR, the protein was distributed throughout 
different brain regions. The quantitative amounts of each protein in the brain homogenates 
(picomol/g brain) were determined using a newly developed near IR fluorescence (NIRF) imaging 
method.23 With the same condition, the amount of albumin is higher than IgG mAb, suggesting 
the delivery of a larger size molecule such as IgG mAb was more difficulty than that of a smaller 
size albumin.23 Using the same condition, the study found that ADTC5 did not enhance the 
delivery of 220 kDa fibronectin, suggesting a potential cut-off size that can be delivered is 220 
kDa.23 
 Recently, we developed novel cyclic peptides with N- to C-terminal cyclization derived from 
the HAV6 and ADTC5 peptide to improve conformational rigidity, target selectivity for cadherin, 
and plasma stability.24 It was shown cyclic peptides HAVN1 (Cyclo(1,6)SHAVSS) and HAVN2 
(Cyclo(1,5)SHAVS) significantly enhanced the brain delivery of 150 kDa IgG mAb compared to 
control while linear HAV6 did not increase the brain delivery of IgG mAb.24 Finally, a cyclic 
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ADTHAV (Cyclo(1,8)TPPVSHAV) with a sequence combination from ADTC5 and HAV6 has a 
better BBB modulatory activity than its linear counterpart.24 The results suggest that N- to C-
terminal cyclization could improve the selectivity and BBB modulatory activity of cadherin 
peptides.24 
HAV6 has also been shown to deliver anticancer drug adenanthin into the brain of mice with 
medulloblastoma brain tumor.25 Adenanthin is a substrate for the efflux pump, P-glycoprotein 
(Pgp); thus, adenanthin alone cannot effectively penetrate the BBB. In this study, multiple 
treatments with HAV6+adenanthin and adenanthin alone were compared to no-treatment in mice 
with medulloblastoma brain tumor (i.e., D425-Med-Luc tumors). The group treated with 
HAV6+adenanthin shown significant suppression of brain tumors compared to adenanthin-treated 
and non-treated groups.25 In addition, HAV6+adenanthin group had a median survival of 30 days 
post-tumor cell injection. In contrast, the median day of survival after tumor cell injection for Ade-
alone was 20 days, which was similar to that of  non-treated groups (19 days).25 About 50% of 
HAV6+adenathin-treated group was able to complete a five cycle-treatment, which resulted in 45 
days of survival post tumor cell injection. These mice showed a complete elimination of brain 
tumor as detected by bioluminescence imaging.25 These results support the potential applicability 
of HAV6 peptide and other cadherin peptides (i.e., ADTC5, ADTHAV, HAVN1, HAVN2) for 
delivering therapeutic agents in models of brain diseases. 
Throughout the course of our studies, we found that the in vivo I.V. administration small and 
large molecules in mice was a better and more sensitive method than the in-situ rat brain perfusion 
method. Previously, ADTC5 has been used to deliver 3H-PEG-1500 and 14C-PEG-40,000 into the 
brain using in-situ rat brain perfusion method.20 However, the results gave a trend of enhanced 
brain delivery for both PEG molecules when co-delivered with ADTC5 but these enhancements 
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were not statistically significant when compared to control.20 In that study, the delivered 
radioactive PEG molecules were diluted with the non-radioactive PEG; thus, the detected 
radioactivity was a fraction of delivered molecules in the brain. In contrast, the brain deposition of 
IRdye800CW-labeled 25 KDa PEG was significantly higher when administered with a cadherin 
peptide (HAV6) compared to without the peptide using in vivo I.V. administration with 15 min 
circulation time.21 The differences in results in brain delivery of molecules (i.e., PEGs or proteins) 
in the in-situ rat brain and in vivo delivery method in mice could be attributed to the differences in 
experimental conditions in these two methods. In the in-situ rat brain perfusion method, the BBB 
exposure time to ADTC5 and PEG molecules was only 2 min with one pass perfusion through the 
BBB vasculature before detecting deposition of delivered molecules in the brain. In contrast, in 
vivo delivery via I.V. administration of IRdye800CW-labeled molecules with cadherin peptides 
(i.e., ADTC5 or HAV6) has 15 min circulation time; thus, the BBB exposure to the administered 
molecule was longer than those in the in-situ rat brain perfusion studies. We also found that the 
dose of delivered molecules and the labeled used to detect the molecule could help the quantitation 
of the delivered molecules in the brain. 
A common concern of our method is extended duration of BBB modulation that allows 
unwanted molecules to cross the BBB into the brain. Using in vivo MRI studies to detect the 
delivery of 65 kDa albumin in living mice, we have demonstrated a significant brain deposition of 
galbumin after I.V. administration of the ADTC5 + galbumin mixture compared to administration 
of galbumin alone.22 When the mice were pretreated with ADTC5 followed by administration of 
galbumin 10 min later, galbumin was still detected in the brain; however, galbumin was no longer 
detected in the brain when it was administered 40 min after ADTC5. These results indicate that 
the BBB porosity increase due to ADTC5 modulation returns to normal after 10 to 40 min. This is 
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a short duration of opening for modulation of the BBB compared to the “osmotic method’s” use 
of a hypertonic mannitol solution that disrupts the BBB for several hours. Previously, we have 
demonstrated that the ex vivo intercellular pathology of the BBB of mice treated with ADTC5 after 
both two and four hours shows a BBB appearance similar to that of untreated, healthy mice, 
indicating that BBB modulated by ADTC5 is reversible to normal BBB conditions.20 In the present 
study, multiple I.V. injections of ADTC5 in the presence of BDNF up to eight times did not show 
any toxicity to the mice. These findings in aggregate suggest that BBB modulation using ADTC5 
is reversible, nontoxic, and does not induce long term effects on the BBB junctions.  
It is proposed that modulation of the BBB by cadherin peptides (i.e., ADTC5 and HAV6) to 
increase paracellular porosity is due to their binding to cadherins and inhibiting cadherin-cadherin 
interactions in a reversible and dynamic fashion. Cadherin-cadherin interactions are part of cell-
cell adhesion and act as “Velcro” in the adherens junctions of the BBB, and ADTC5 and HAV6 
peptides have been shown to enhance the penetration of molecules through the paracellular 
pathway.1, 20 NMR binding studies between ADTC5 or HAV6 peptide to the EC1 domain of E-
cadherin have indicated that each peptide binds to a different region of the EC1 domain. From 
these binding studies, ADTC5 is proposed to bind to the EC1-EC1 domain swapping region by 
blocking the EC1-EC1 trans-cadherin interactions to increase paracellular porosity. In contrast, 
HAV6 peptide is proposed to interact with the EC1 domain to block cis EC1-EC2 cadherin 
interactions. Although both peptides bind to different sites on the EC1 domain of E-cadherin, they 
are able to modulate cadherin interactions in the BBB.19, 20 E-cadherin is primarily found in 
epithelial cells such as intestinal mucosa epithelium, and VE-cadherin (cadherin-5) is expressed in 
peripheral endothelium. However, it is still not clear whether the BBB has only VE-cadherin or a 
combination E- and VE-cadherins. In Western blots analysis, anti-E-cadherin antibody but not 
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anti-VE-cadherin (anti-cadherin-5) can detect cadherin in the homogenates of bovine brain 
microvessel endothelial cells (BBMEC).61 It has been suggested that cadherin in the intercellular 
junction of the BBB has E-cadherin-like properties and that the VE-cadherin might be contributing 
to the BBB function.62, 63 Thus, there is still a need to study the selectivity of cadherin peptides to 




The present study has demonstrated that BDNF can be delivered to the brains of mice via 
systemic administration using ADTC5 as a BBB modulator. To the best of our knowledge, this is 
the first demonstration of non-invasive delivery of BDNF that suppresses disease relapse in EAE 
mice, an animal model for multiple sclerosis. Multiple I.V. administrations of BDNF + ADTC5 
significantly improve the clinical body scores of EAE mice compared to mice that received BDNF 
alone, ADTC5 alone or vehicle. BDNF can permeate the BBB and exert an immediate effect to 
upregulate pTrkB receptors. Additionally, delivered BDNF was shown to induce remyelination 
and increase the presence of NG2 glia cells as well as stimulate downstream EGR1 and ARC 
mRNA transcripts. These results demonstrate that ADTC5 could be used to modulate the BBB to 
improve non-invasive brain delivery of BDNF or other proteins to treat brain diseases. Further 
studies are being conducted for brain delivery of various sized proteins in healthy and brain disease 
animal models. 
 
2.6. Figures and Figure Legends: 
   87 
 
Figure 2.1. The effect of treatment of SJL/elite EAE mice, an animal model for MS, with 
BDNF (5.71 nmol/kg) + ADTC5 (10 µmol/kg; n = 7 ), BDNF alone (5.71 nmol/kg; n = 6), 
ADTC5 alone (10 µmol/kg; n = 5), or vehicle (n = 5) during remission on days 21, 25, 29, 33, 
37, 4;1, 45, and 48.  (A) Clinical disease score vs. time of mice treated 8 times with either 
BDNF + ADTC5, BDNF alone, ADTC5 alone or vehicle; arrows indicate treatment days. (B) 
Comparison of area under the curve (AUC) of the disease scores from days 21–55 from EAE 
mice treated with BDNF + ADTC5, BDNF alone, ADTC5 alone, or vehicle. *p ≤ 0.05; one-
way ANOVA (95% confidence). 
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Figure 2.2. The effects of BDNF (5.71 nmol/kg) + ADTC5 (10 µmol/kg), BDNF alone (5.71 
nmol/kg), or vehicle treatments on remyelination in the lateral corpus callosum and surrounding 
cortex of the brains of SJL/elite EAE mice as stained by Luxol fast blue. (A) Greyscale, the binary 
conversion, and color photomicrograph of myelin images taken under identical exposure of the 
lateral corpus callosum of EAE mice treated with BDNF + ADTC5, BDNF Alone, or vehicle; red 
arrows indicate breakages in the myelin (B) Quantitative myelin densiometric comparison in the 
brain of BDNF + ADTC5, BDNF Alone, and vehicle treated EAE mice; Scale bar = 50 µm; **p 
≤ 0.01 ***p ≤ 0.001; one-way ANOVA (95% confidence; n = 5). 
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Figure 2.3. The effects of BDNF (5.71 nmol/kg) + ADTC5 (10 µmol/kg), BDNF Alone (5.71 
nmol/kg), or vehicle treatments on presence of NG2 receptor in the medial corpus callosum of 
brains of SJL/elite EAE mice as stained by DAB. (A) Color photomicrograph of anti-NG2 staining 
(brown) taken under identical conditions from the medial corpus callosum for mice treated with 
BDNF + ADTC5, BDNF alone, vehicle; red arrows point to dense regions of activated NG2-glia. 
(B) Quantitative NG2 density comparison amongst the EAE mice treated with BDNF + ADTC5, 
BDNF alone, and vehicle; Scale bar = 50 µm; **p ≤ 0.01; one-way ANOVA (95% confidence; n = 
5). 
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Figure 2.4. The effects of BDNF (5.71 nmol/kg) + ADTC5 (10 µmol/kg), BDNF alone (5.71 
nmol/kg), or vehicle treatments on mRNA expression of EGR1 and ARC in the cortex of the brains 
of SJL/elite EAE mice. (A, B) Photomicrograph of DAPI (blue), EGR1 (green), ARC (magenta), 
and composite images taken of the cortex of the midbrain (A) and hindbrain (B) of EAE mice 
treated with BDNF + ADTC5, BDNF alone, or vehicle. (C) Quantitative comparison of EGR, 
ARC, and NOS1 mRNA transcript expression, as determined by cell count, for mice treated with 
BDNF + ADTC5, BDNF alone, or vehicle. (D) Quantitative comparison of DAPI cell count; Scale 
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bar = 50 µm; ***p ≤ 0.001; one-way ANOVA (99% confidence; n = 5).  Contrast and brightness 
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Figure 2.5. Western blot detection of recombinant BDNF and pTrkB from mice treated with either 
BDNF + ADTC5 or BDNF alone. (A) Western blot probing for recombinant BDNF in the brains 
of mice that received BDNF (5.71 nmol/kg) + ADTC5 (10 µmol/kg; A1, A2, A3) or BDNF alone 
(5.71 nmol/kg, B1, B2, B3); ‘L’ represents molecular weight ladder; ‘+’ represents the positive 
control of recombinant BDNF; red arrows highlight increased recombinant BDNF detection. (B) 
Western blot probing for recombinant BDNF after dosage increase in healthy mice that received 
BDNF (57.1 nmol/kg) + ADTC5 (10 µmol/kg; A1, A2),  BDNF (28.6 nmol/kg) + ADTC5 (10 
µmol/kg; A3), or ), BDNF alone (28.6 nmol/kg; B1, B2, B3); red arrows highlight increased 
recombinant BDNF detection. (C) Western Blot probing for pTrkB after dosage increase of 
healthy mice that received BDNF (57.1 nmol/kg) + ADTC5 (10 µmol/kg; A1, A2), BDNF (28.6 
nmol/kg) + ADTC5 (10 µmol/kg; A3), or  BDNF alone (28.6 nmol/kg; B1, B2, B3); red arrows 
highlight increased pTrkB detection. (D) Total protein stain (loading control) for samples treated 
with BDNF 57.1 nmol/kg or 28.6 nmol/kg in B and C. (E) Graphical representation of recombinant 
BDNF detection level in mice that received BDNF (57.1 nmol/kg) + ADTC5 (10 µmol/kg; A1, 
A2), BDNF (28.6 nmol/kg) + ADTC5 (10 µmol/kg; A3), or BDNF alone (28.6 nmol/kg; B1, B2, 
B3). (F) Graphical representation of pTrkB detection level for mice that received BDNF (57.1 
nmol/kg) + ADTC5 (10 µmol/kg; A1, A2), BDNF (28.6 nmol/kg) + ADTC5 (10 µmol/kg; A3), or 
BDNF alone (28.6 nmol/kg; B1, B2, B3). (G) Graphical representation of total protein loaded 
among all groups. Contrast and brightness of images were adjusted only for display purposes. 
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Chapter 3: Efficacy Evaluation of Non-Invasive Brain Delivery of BDNF in 
APP/PS1 Transgenic Mice 
3.1. Introduction: 
To date, effective treatments for Alzheimer’s disease (AD) have remained elusive. Currently, 
treatment of Alzheimer’s disease focuses on managing symptoms by regulating neurotransmitter 
levels in the CNS and peripheral nervous system. Acetylcholinesterase inhibitors such as donepezil 
(Aricept®),1 rivastigmine (Eexelon®),2 and galantamine (Razadyne®),3 have been the primary 
choice of treatment for those with moderate to severe AD. Additionally, N-methyl-d-aspartate 
(NMDA) receptor regulators, such as memantine (Namenda®)4 or a combination of 
acetylcholinesterase inhibition and NMDA regulators (Namzaric®) have been used to treat AD.5, 
6  While these treatments may aid in temporary relief of symptoms such as moderate confusion, 
sleeplessness, agitation, anxiety, and aggression, their benefits are almost always temporary and 
ultimately these drugs prove to be highly cost ineffective.1, 7 Thus, there is an urgent need to find 
early diagnostic and therapeutic solutions to halt or reverse progress of the disease. 
Within the past two decades there have been extensive attempts to develop “disease-modifying 
drugs” rather than “symptom-suppression drugs.” To block the progression of Alzheimer’s, 
developed drugs must interfere with the pathogenic steps responsible for the manifestation of 
clinical symptoms. Such pathogenic steps include the early build-up of extracellular amyloid-beta 
plaques, the intercellular build-up of neurofibrillary tangle Tau formations, neuroinflammation, 
oxidative damage, metal ion deregulation, and cholesterol metabolism.8 There has been a 
tremendous effort to develope therapeutics based on preventing the formation of or removing the 
amyloid-beta (Ab) plaques in the brain. These potential treatments include enzyme inhibitors, anti-
Ab monoclonal antibodies (mAbs), and immunotherapies. The use of active vaccine therapies, 
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AN1792 and CAD106, has not been successful due to unforeseen side effects or low efficacy. In 
the case of AN1792, selected treated patients developed T cell-mediated meningoencephalitis.9 
CAD106 was the only vaccine to advance to phase-3 trials for prevention of Alzheimer’s disease; 
however, the trial results have indicated that such vaccine treatments may be too little too late to 
provide a significant effect.10 Active vaccination for treatment of AD was met with additional 
challenges, including immune response that varies with the age of patients with AD and the 
propensity for adverse effects. To avoid the complications from active vaccination of AD patients, 
passive immunization has arisen as an attractive alternative for AD. Thus, administration of mAbs 
therapeutics ensures consistent and controlled antibody titers in which adverse side effects can be 
controlled by halting the treatment. The primary drawback of mAb treatments is its high cost due 
to the repeated doses and expensive cost of antibody production.10, 11 
Several mAbs have undergone through extensive development and clinical trials for the 
treatment of AD; however, to date, none have gained FDA approval for the treatment of AD or 
other CNS diseases regardless of the extensive target validation, in vitro success, and excellent PK 
and safety profiles. Bapineuzumab (AAB-001) was the first antibody drug to reach phase-2 clinical 
trials for AD since AN1792. Unfortunately, no significant treatment outcomes such as 
improvement in disability assessment for dementia scores were observed; thus, the trial was 
discontinued due to the lack of positive results. Since bapineuzumab, at least seven mAbs were 
evaluated for AD treatment without success.10, 12, 13 Most recently, after being abandoned, 
aducanumab has been reevaluated following an additional analysis of clinical trials data. 
Alternatively, neurotrophic agents such as brain-derived neurotrophic factor (BDNF), nerve 
growth factor (NGF), and insulin-like growth factor have been investigated for the treatment of 
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AD.14, 15 Similar to mAbs, these neurotrophic proteins have met with challenges for their use in 
the treatments of AD. 
One potential hypothesis for the vast failure of mAbs and other proteins as therapeutics for the 
treatment of AD is their inefficiency in crossing the blood-brain barrier (BBB) with the necessary 
or sufficient dose to exude their biological activities. Several efforts to improve delivery of mAbs 
and other proteins into the brain such as osmotic BBB disruption (BBBD),16-18 “Trojan Horse” 
delivery method,19 and ultrasound with microbubbles20, 21 have shown various levels of success. 
We also utilized cadherin peptides as BBB modulators (BBBM) to improve brain delivery of 
molecules across the BBB. Linear and cyclic cadherin peptides as BBBM (i.e., HAV6, ADTC5, 
HAVN1, HAVN2, and ADTHAV) can improve brain delivery of various sizes of proteins (e.g., 
15 kDa lysozyme, 65 kDa albumin, 150 kDa mAb) with different brain deposition levels in 
C57BL/6 mice.22-24 Brain delivery of adenanthin, an anticancer drug, with the help of HAV6 
peptide as a BBBM has been shown to suppress medulloblastoma brain tumor growth and increase 
survival in the mouse model compared to placebo animals and animals treated with adenanthin 
alone.25 Recently, we treated experimental autoimmune encephalomyelitis (EAE) mice during 
disease remission with eight injections of BDNF+ADTC5, BDNF alone, ADTC5 alone, and PBS. 
The results showed that treatment with BDNF+ADTC5 suppressed disease relapse while 
treatments with BDNF alone, ADTC5 alone, and PBS did not.  
In the present study, we evaluated the effects of non-invasive systemic delivery of BDNF into 
the brain using ADTC5 peptide compared to BDNF alone in APP/PS1 transgenic mice and 
negative control groups. The AD symptoms of treated APP/PS1 transgenic mice were monitored 
using cognitive evaluation methods, including Y-maze and novel object recognition assessments. 
The effects of BDNF brain delivery were also determined by evaluating activated downstream 
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cellular processes known to be affiliated with neuroregeneration such as NG2, EGR1, and Arc 
upregulations. 
 




All animal studies were carried out under the approved animal protocol (AUS-74-11) granted 
by Institutional Animal Care and Use Committee (IACUC) at The University of Kansas. Animal 
Care Unit (ACU) personnel and veterinarians were involved in the care of the animals used in this 
study. Female transgenic APP/PS1 (MMRRC stock # 34832-Jax) were obtained from The Jackson 
Laboratory (Bar Harbor, ME) and housed until at least 6 months of age. Mice received i.v. 
injections of either BDNF (5.7 nmol/kg) + ADTC5 (10 µmol/kg; n = 7), BDNF alone (5.7 nmol/kg; 
n =6), or vehicle (n = 6) every 4 days, for a total of 8 injections. At the end of the study, the mice 
were euthanized via CO2 inhalation and perfused with PBS immediately followed by 4% formalin 
fixative. The brains were extracted and post-fixed overnight in the perfusion-fixation solution. 
 
3.2.2. Cadherin Peptide Synthesis and Purification: 
 
Cadherin Peptide Synthesis and Purification: 
ADTC5 peptide was synthesized using a solid-phase peptide synthesizer (Gyros Protein 
Technologies, Tucson, AZ) as described previously.23  Briefly, crude peptide was cleaved from 
the resin with TFA containing scavengers followed by precipitation in cold diethyl ether. The  
disulfide bond in ADTC5 was formed by stirring the linear peptide precursor in 0.1 M ammonium 
bicarbonate buffer solution at pH 9.0 in high dilution while bubbling air through the solution. The 
cyclic ADTC5 was purified using  a semi-preparative HPLC X-bridge C18 column (Waters, 
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Milford, MA) and the product was analyzed by analytical HPLC to be > 95 % pure. The exact 
mass of cyclic ADTC5 was determined by mass spectrometry. 
 
3.2.3. Y-maze Assessment: 
 
Twenty-four hours following the 8th injection, the mice were subject to Y-maze behavioral 
assessment. First the mice were habituated to the maze for 8 min with one arm of the maze closed 
off. Three hours following habituation, the mice were re-introduced to the maze for 5 min with all 
three arms open. All mice were initially placed in the center of the maze oriented toward the same 
arm; the maze was thoroughly cleaned with 70% ethanol and Virkon between each trial to remove 
scent cues. Time in Novel Arm was defined as the percent of total time (5 min) spent in the third 
arm of the maze (previously closed-off arm). An entry into an arm was defined as the head of the 
mouse entering. 
 
3.2.4. Novel Object Recognition Assessment: 
 
Twenty-four hours following the Y-maze assessment the mice were subjected to Novel Object 
Recognition (NOR) assessment. First, mice were individually habituated in an empty open field 
for 5 min. Twenty-four hours after habituation, 2 identical objects were placed in the open field, 5 
cm away from the wall; there were two different sets of identical objects that were randomly 
selected for each mouse. Mice were individually placed in the field facing away from the objects 
and were allowed to familiarize themselves with the objects for 10 min. 24 h following 
familiarization, mice were re-subjected to the open field, but one of the objects was replaced with 
a novel object; the position of the novel object (right or left side) was randomized for each mouse. 
The mice were allowed to explore the objects for 10 min and the total amount of time each mouse 
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spent interacting with each object was measured. For all steps, the open field and object were 
cleaned with 70% ethanol and Virkon.  
 
3.2.5. Euthanasia, Brain Perfusion, and Extraction: 
 
At the end of the study, mice were euthanized via CO2 inhalation and perfused with PBS 
immediately followed by 4% formalin fixative. The brains were extracted and post-fixed overnight 
in the perfusion-fixation solution then transferred to 70% ethanol PBS solution for paraffin 
embedding.  
 
3.2.6. Histology and Immunohistochemistry: 
 
Coronal brain sections (10 μm thickness) from were sectioned and mounted onto gelatin-
coated slides (Superfrost Plus, Thermo Fisher Scientific, Walmath, MA). For both amyloid beta 
histology and anti-NG2 immunohistochemistry, sections were deparaffinized using xylene and 
serially hydrated from 95% ethanol to distilled water. For amyloid beta, slides were stained with 
Congo Red Solution (Abcam, Cambridge, UK) for 20 min, then dipped in twice in 100% ethanol, 
cleared with xylene, mounted using synthetic Permount (Fisher Scientific, Hampton, NH) and 
covered using 2.5 coverslips. Amyloid plaque levels were quantified by counting the number of 
plaques from the hippocampus at 10X magnification from 5 random sections per group (n = 5). 
For anti-NG2 staining, slides were first blocked in a 3% hydrogen peroxide blocking agent 
then subsequently rinsed using distilled water. Next, heat-induced isotope retrieval (HIER) was 
performed using a 10 nM sodium citrate, 0.05%, pH 6.0 buffer. In brief, the HIER buffer was 
brought to a boil and slides were submerged for 15 min and then immediately rinsed with PBS, 
0.05% Tween-20 (PBS-T) buffer for 3 min. Slides were then blocked using 10% normal BSA for 
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6 min and subsequently rinsed with water. The NG2 primary antibody (Abcam) was then applied 
to the slides in a dilation of 1:1,000 in PBS-T and they were incubated overnight at 4 ºC in a moist 
chamber. The following steps were performed using the Polink-2 HRP Plus Rabbit DAB Detection 
System for Immunohistochemistry (Golden Bridge International Labs, Bothell, WA). Briefly, 
Rabbit Antibody Enhancer (Reagent 1) was applied to the slides and incubated at room 
temperature for 30 min. The slides were then rinsed with PBS-T and Polymer-HRP for Rabbit 
(Reagent 2) was applied, after which they were incubated at room temperature for 30 min. The 
slides were then rinsed with PBS-T and the chromogen was applied; to prepare the chromogen, 2 
drops of DAB Chromogen (Reagent 3B) were added to DAB Reagent buffer (Reagent 3A). The 
slides were incubated with the DAB mixture for 10 min and then rinsed with water. Lastly, the 
slides were dipped into 100% ethanol twice, dried, mounted using Permount, and coverslipped 
using 1.5 coverslips. Anto-NG2-stained slides were imaged using a Leica DM750 Compound 
Bright Field Upright Microscope and imaged at 40x magnification under identical exposure times. 
Anti-NG2 levels were quantified via densitometry analysis at 40x magnification from 5 random 
sections per group (n = 5). 
 
3.2.7. Fluorescent in Situ Hybridization: 
 
Coronal brain sections (10 μm thickness) were sectioned and washed three times in PBS before 
mounting on gelatin-coated glass slides (Superfrost Plus, Thermo Fisher Scientific). Tissues were 
allowed to dry at RT and were then stored at –20 ºC until use. Fluorescence in situ hybridization 
(FISH) was performed using RNAscope® Technology 2.0, Advanced Cell Diagnostics (ACD), 
Hayward, CA) Multiplex Reagent Kit V2.26-28 In short, mounted tissue sections were 
deparaffinized using xylene and serially dehydrated in 50%, 70%, 95%, and 100% ethanol for 
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5 min each. Between all pretreatment steps, tissue sections were briefly washed with nanopure 
water. Pretreatment solution 1 (hydrogen peroxide reagent) was applied for 10 min at RT, and then 
the tissue sections were boiled in pretreatment solution 2 (target retrieval reagent) for 15 min. 
Mounted slices were pretreated with solution 3 (protease reagent) for 30 min at 40 ºC in the 
HybEz™ hybridization system (ACD). Following tissue pretreatment, the following transcript 
probes were applied to all sections:  Mm-Mapk1-C1 (Cat. # 458161), Mm-Arc-C2 (Cat. # 316911-
C2), and Mm-Egr1-C3 (Cat. # 423371-C3), which correspond to mitogen-activated protein kinase 
1 (Mapk1, activity-related cytoskeleton-associated protein (Arc), and early growth response 1 
(Egr1), respectively. Probes were hybridized to sections for 2 h at 40 ºC and subsequently washed 
for 2 min at room temperature. Following hybridization, hybridize AMP 1 was applied to each 
slide, which was then incubated for 30 min at 40 ºC. The same process was repeated for hybridize 
AMP 2 and 3. For HRP-C1 signal development (Mapk1), HRP-C1 was applied to the slides, and 
they were incubated for 15 min at 40 ºC and then washed. For C1, Opal® 650 (Akoya Biosciences, 
Menlo Park, CA) was applied and incubated for 30 min at 40 ºC and then washed. Following the 
wash, HRP blocker was applied to each slide, which was incubated for 15 min at 40 ºC and then 
washed. This process was repeated for C2 (Arc), and C3 (Egr1) using Opal® 620 and 520, 
respectively. The resulting transcript-fluorophore labeling is as follows: Mapk-650, Arc-620, 
EGR1-520. All sections were counterstained by incubating DAPI for 30 sec at RT following by 
rinsing. Slides were then covered using ProLong Gold Antifade Mounting Media and 1.5 
coverslips. Slides were allowed to dry in the dark overnight at 4 ºC. All sections were imaged 
within 2 weeks.  
Fluorescent images were taken using an Olympus Inverted Epifluorescence Microscope XI81 
(Olympus Life Solutions, Waltham, MA) running SlideBook Version 6.0 (3i, Ringsby, CT) 
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equipped with a digital CMOS camera (2000x2000), automatic XYZ stage position, ZDC 
autofocus, and a xenon lamp excitation source. Images were taken under identical exposure times 
(100 msec) using a 40x objective and appropriate filter sets for each fluorophore (i.e., DAPI–
DAPI, FITC–Opal® 520, Texas red–Opal® 620, and Cy 5.5–Opal® 650). To determine the degree 
of mRNA transcript expression, 4 images of the CA1 region of the hippocampus regions were 
randomly selected from mouse samples of each group, and the total fluorescence signal intensity 
for each channel was quantified. For display purposes, images were pseudo-colored and 
brightness-adjusted using ImageJ; green was assigned to Opal® 520 (EGR1), red to Opal® 620 
(ARC), cyan to Opal® 650, and grey to DAPI.   
 
3.2.8. Statistics and Data Analysis: 
 
All statistics and data analyses were performed using GraphPad Prism (San Diego, CA). 
Analysis of variance (ANOVA) and Student’s T-test were performed when appropriate, both 
operating at 95% confidence intervals with a p-value of less than 0.05 used as the criterion for 




3.3.1. Effect of BDNF on Cognitive Performance in Y-maze and NOR Assessment: 
 
The ability of ADTC5 to deliver BDNF into the brains of mice after I.V. injection was assessed 
by determining the effects of BDNF on improving cognitive function in APP/PS1 Alzheimer’s 
disease animal model as determined by Y-maze and NOR assessments. The efficacy of BDNF 
(5.71 nmol/kg) + ADTC5 (10 µmol/kg; n = 7) was compared to that of BDNF alone (5.71 nmol/kg; 
n = 6), and vehicle (n = 6). Once mice reached 6 months of age, i.v. injections were administered 
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every 4 days for a total of 8 injections. Twenty-four hours following the final injection, mice were 
subjected to Y-maze and NOR assessments.  
For the Y-maze, mice that received BDNF + ADTC5 performed significantly better than mice 
that received BDNF alone or vehicle (Figure 3.1). The mice that received BDNF + ADTC5 spent 
a greater percentage of time (F(2,15) = 3.99; p < 0.05) and had a higher number of entries (F(2,15) = 
5.63; p < 0.05) into the third arm of the maze than did the groups that received BDNF alone or 
vehicle (Figure 3.1).  
For the NOR assessment, the mice that received BDNF + ADTC5 performed significantly 
better than mice that received BDNF alone or vehicle. The mice that received BDNF + ADTC5 
spent a greater percentage of time with the novel object (F(2,16) = 6.55; p < 0.01) than did the mice 
that received BDNF alone or vehicle (Figure 3.2). Lastly, there was no significant difference in 
total time spent with either of the two objects (i.e., all groups spent similar amounts of time 
interacting with either object; F(2,16) = 0.682; p = 0.52; Figure 3.2). 
 
3.3.2. Effect of BDNF Delivery on Amyloid Beta Plaques in Hippocampus: 
 
The means by which BDNF delivery to the brain improved cognitive performance in mice was 
investigated by comparing the amount of amyloid-beta plaques in mice that received BDNF + 
ADTC5, BDNF alone, or vehicle. Our results indicated that all groups expressed high variability 
levels of plaques in the hippocampus regardless of the treatment and there was no significant 
difference in the number amyloid beta plaques across groups (F(2,12) = 0.096; p = 0.91, n = 5; 
Figure 3.3). 
 
   113 
 
3.3.3. Effect of BDNF Delivery on NG2-Glia:  
 
We have previously demonstrated that BDNF delivery to EAE mice via ADTC5 induced 
oligodendrocyte maturation via significant increased levels of NG2 receptors. Furthermore, others 
have shown that BDNF+/+ mice demonstrate distinct upregulation of NG2 glia following the 
development of cuprizone-induced lesions compared to BDNF+/- and BDNF-/- mice.29, 30  We 
probed whether BDNF delivery via ADTC5 would induce oligodendrocyte maturation in the 
APP/PS1 mouse model by staining for anti-NG2 in the cortex. A higher degree of NG2 staining 
as indicated by a darker/lower pixel value was found in mice that received BDNF + ADTC5 
compared to the mice received either BDNF alone or vehicle (Figure 3.4); F(2,12) = 11.16; p < .01, 
n = 5. 
 
3.3.4. Effect of BDNF on EGR1, ARC, and MAPK1 mRNA Transcript Expression: 
 
BDNF is known to stimulate to stimulate downstream transcription factors such as, 
tropomyosin  receptor kinase B (TrkB), mitogen-associated protein kinase 1 (MAPK1) cyclic 
AMP response element binding protein (CREB), early growth response-1 (EGR1), and activity-
related cytoskeleton associated protein (ARC).31-33 We have previously demonstrated that 
delivering BDNF via ADTC5 to EAE mice results in an increase in EGR-1 and ARC mRNA 
transcript expression. Additionally, others have shown that EGR1 directly targets ARC 
expression.34, 35 We quantified levels of EGR1, ARC, and MAPK1 mRNA transcripts via 
fluorescence in situ hybridization (FISH). Figure 3.5 shows brain sections from the CA1 region 
of the hippocampus. Mice that  received  BDNF + ADTC5 show significant increases in EGR1 
(F(2,9) = 23.48; p < 0.001, n = 5) and ARC (F(2,9) = 7.33; p < 0.05, n = 5) transcript levels compared 
to mice that received BDNF alone or vehicle; very high  levels of MAPK1 expression were found 
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in all groups; however, no significant differences were observed (F(2,9) = 0.08; p = 0.92, n = 5; 




In this study, we delivered BDNF using ADTC5 into the brains of transgenic APP/PS1 mice, 
which is an animal model for AD. BDNF was chosen because it is endogenous in nature, thus 
posing low potential for adverse side effects in transgenic APP/PS1 mice. Because BDNF alone 
cannot penetrate the BBB, the hope was that BDNF with the help of ADTC5 could enter the brain 
and exert its activity to induce neuro-regeneration. The results from this study showed that we 
have demonstrated that multiple systemic injections of BDNF+ADTC5 can significantly improve 
cognitive performance and activate downstream cellular processes known to be associated with 
BDNF exposure when compared to injections of BDNF alone or vehicle. This suggests that 
ADTC5 enhanced the brain delivery of BDNF. The mice treated with BDNF+ADTC5 
demonstrated a statistically significant performance in Y-Maze and NOR behavioral assessments 
compared to mice that received BDNF alone or vehicle. Furthermore, mice that received BDNF + 
ADTC5 showed a significant increase in NG2 glia, EGR1, and ARC mRNA transcripts compared 
to mice that received BDNF alone or vehicle (Figures 3.4 & 3.5).  
In the EAE animal model, a model for multiple sclerosis, multiple injections of 
BDNF+ADTC5 were able to ameliorate EAE symptoms, induce remyelination, promote NG2 glia 
maturation, and upregulate ARC and EGR1 compared to mice that received BDNF alone, or 
vehicle. In the same study, BDNF delivered with ADTC5 could be detected in the brain 
homogenates using Western blot analysis. In contrast, when BDNF was delivered alone, there was 
virtually no detectable signal of recombinant BDNF in the Western blots of the brain homogenates. 
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In the same study, administration of BDNF+ADTC5 stimulated the phosphorylation of TrkB in 
the brain as a marker of BDNF brain delivery while administration of BDNF alone did not trigger 
TrkB phosphorylation, indicating that BDNF alone could not penetrate the BBB. Additionally, 
ADTC5 alone did not produce the activity to improve EAE scores, suggesting that it has no 
inherent neuro-regenerative properties. Here, we show in a different animal model that ADTC5 
can be used to deliver BDNF to improve disease symptoms. 
Another cadherin peptide, HAV6, was used as BBB modulator to improve the brain delivery 
of adenanthin (ade), an anticancer drug, to treat medulloblastoma brain tumor.23 Although 
adenanthin is a hydrophobic and soluble molecule, it cannot cross the BBB because it is a substrate 
for the efflux pump, P-glycoprotein (Pgp). In healthy mice, the brain delivery of adhenathin was 
significantly enhanced by its co-administration with HAV6.23 In a medulloblastoma animal model, 
multiple treatments with a combination of adenanthin and HAV suppressed the brain tumor growth 
and increased animal survival compared to those treated with adenanthin alone or placebo.23 In 
some case, additional treatment with the adenanthin + HAV6 eliminated the brain tumor 
completely. In addition, multiple treatments with HAV6 did not induce microglia activation and 
astrogliosis, which normally occur due to neuroinflammation. This study suggests the potential 
viability of modulating the BBB with cadherin peptides to deliver therapeutics for brain tumors.  
Recently, ADTC5 has been shown to improve brain delivery of 15 kDa lysozyme, 65 kDa 
albumin, and 150 kDa IgG mAb in C57BL/6 mice.21,22 However, ADTC5 could not deliver 220 
kDa fibronectin into the brain, suggesting that there is a size limit of molecules that can be 
delivered into the brain. It is interesting to discover that ADTC5 created time- and size-dependent 
of opening of pores in the intercellular junctions of the BBB. The time-dependent opening of the 
BBB was evaluated using a pretreatment experiment to determine the reversibility of the pore 
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openings. In this case, ADTC5 was administered first and, after a certain number of minutes, 
different sizes of molecules were delivered. The result showed that ADTC5 allowed the BBB 
permeation of a small molecules such as gadopentetic acid (Gd-DTPA) in a time window of 2 h; 
however, no molecules could pass through the BBB after 4-h delay. In contrast, ADTC5 allowed 
only 65 kDa albumin to enter the brain after 10-min delay, but no albumin could enter the brain 
after 40-min delay. Finally, the maximum delay time allowed for IgG mAb to penetrate the BBB 
was less than 10 min. These results suggest that the large pore openings created by ADTC5 
collapse to smaller pores in a time-dependent manner. Taken together, ther results show that 
ADTC5 has the robust activity to modulate the BBB for improved entrance of small and large 
molecules. 
In this study, the Y-maze and NOR behavior assessments were used to evaluate cognitive 
performance because these methods have been well established and validated. In preclinical 
studies, they have been  widely used to assess cognitive impairment in transgenic animals that is 
similar to cognitive tests performed in humans; thus, the results have translational values in 
evaluating potential therapeutics for AD.36-41  The advantage of these assessment methods is that 
the animals do not have to be subjected to stressful conditions like food or water deprivation as 
well as physical stress. Stressful conditions such as those in the Morris water maze could alter the 
cognitive performance. In our studies, animals that received multiple treatments of BDNF + 
ADTC5 had significant behavior improvements in Y-maze and NOR tests compared to the animal 
groups that received BDNF alone or vehicle. Others have found that exercise induces the 
upregulation of BDNF, which leads to the enhancement of brain plasticity; in addition, 
upregulation in BDNF has been associated with improved performance in behavioral tests in AD 
animal models.42-45 Additionally, Bechara et al. (2014) demonstrated that a single 
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intracerebroventricular (i.c.v.) injection of BDNF can mimic exercise-induced brain plasticity and 
result in an improvement in an object displacement task.46  Our results are congruent with those of 
others that indicate that BDNF can be delivered in therapeutically relevant doses using ADTC5 to 
improve cognitive performance.  
To obtain a deeper understanding of how BDNF improves cognitive performance, amyloid-
beta plaques were stained using Congo red and all groups exhibited high levels of plaques (Figure 
3.3). There were no significant differences in the number of amyloid beta plaques among all three 
groups. Our results reflect that of Nagahara et al. (2013) who showed that BDNF delivery using a 
Lenti-BDNF vector demonstrated improved hippocampal-dependent learning but showed no 
reduction in amyloid beta plaques.47 They also demonstrated that BDNF treatment ameliorated 
cell loss and improved synaptophysin immunoreactivity in the hippocampus. Similarly, using 
fluorescence in situ hybridization, we showed an increase in mRNA transcripts (EGR1 and ARC; 
Figure 3.5) associated with synaptic plasticity in the hippocampi of mice treated with BDNF + 
ADTC5 without a reduction in amyloid-beta plaque load (Figure 3). Therefore, it is likely BDNF 
is ameliorating APP/PS1 symptoms by modulating hippocampal plasticity and not by reducing 
amyloid-beta plaque loads. 
NG2 glia are thought to play an integral role in several processes including modulation of 
synaptic response, remyelination, and integration of neurons into synaptic networks.48 Some 
researchers have found that the presence of high amyloid beta-plaque loads and exacerbated 
APP/PS1 symptoms could cause increased levels of NG2 glia as a response to increased 
neuroinflimation.49, 50  Our results indicated a significant increase in NG2 glia in the brains of mice 
that received BDNF + ADTC5 compared to those that received BDNF alone or vehicle (Figure 
3.4). A similar result was observed when we treated EAE mice with  BDNF + ADTC5, BDNF 
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alone, and vehicle; a significant upregulation of NG2 glia in the corpus callosum was found in 
BDNF + ADTC5-treated mice compared to those treated with BDNF alone and vehicle. Similarly, 
Nakajima et al. (2010) showed that targeted retrograde gene delivery of BDNF suppressed 
apoptosis of neurons and oligodendroglia and resulted in a significant promotion of NG2 
expression after spinal cord injury in rats.51  Furthermore, McTigue et al. (1998) demonstrated that 
transplanting fibroblasts producing BDNF into contused adult rat spinal cords resulted in a 
significant increase in expansion of oligodendrocyte lineage cells.52 These combined findings 
provide strong evidence that BDNF delivery can ameliorate CNS damage via promotion of NG2 





This study has shown the potential utility of cadherin peptides such as ADTC5 as blood-brain 
barrier modulators (BBBM) to increase the delivery of BDNF into the brain to improve cognitive 
behavior and neuroregeneration in transgenic APP/PS1 mice as an animal model for AD. ADTC5 
was shown to be effective in delivering BDNF into the brains of the EAE animal model and 
improved the disease symptoms as well as inducing activation remyelination and neuro-
regeneration markers in the brain. In the future, cadherin peptides such as BBBM can be used to 
deliver many other proteins, for example, mAbs, enzymes, neurotrophic factors, and hormones for 
treating brain diseases.  
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3.6. Figures and Figure Legends: 
 
A        B 
 
Figure 3.1. The effect of treatments of APP/PS1 mice, an animal model for Alzheimer’s disease 
with BDNF (5.71 nmol/kg) + ADTC5 (10 µmol/kg), BDNF alone (5.71 nmol/kg), or vehicle on 
Y-Maze cognitive assessment. (A) The percent of total time spent in the maze that mice spent in 
the third arm/novel arm. (B) The total number of entries mice made into the third arm of the maze. 
*p < 0.05; one way ANOVA (95% confidence, n =5). 
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A       B 
 
Figure 3.2. The effect of treatment of APP/PS1 mice with BDNF (5.71 nmol/kg) + ADTC5 (10 
µmol/kg), BDNF alone (5.71 nmol/kg), or vehicle on novel object recognition (NOR) cognitive 
assessment. (A) The percent of total time spent in the open that mice spent exploring/interacting 
with the novel object. (B) The total amount of time mice spent exploring either object. *p < .05; 
one way ANOVA (95% confidence, n =5). 
  




Figure 3.3. The effect of treatment of APP/PS1 mice with BDNF (5.71 nmol/kg) + ADTC5 (10 
µmol/kg), BDNF alone (5.71 nmol/kg), or vehicle on hippocampal amyloid plaque load, as 
determined via Congo red staining. 
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   A        B 
 
Figure 3.4. The effect of treatment of APP/PS1 mice with BDNF (5.71 nmol/kg) + ADTC5 (10 
µmol/kg), BDNF alone (5.71 nmol/kg), or vehicle on the presence of NG2 receptors in the cortex 
as stained by DAB. (A) Color photomicrograph of anti-NG2 staining (brown) taken under identical 
conditions from the cortex of mice treated with BDNF + ADTC5, BDNF alone, and vehicle; red 
arrows point to dense regions of activated NG2-glia. (B) Quantitative NG2 density comparison 
among the APP/PS1 mice treated with BDNF + ADTC5, BDNF alone, and vehicle; Scale bar = 
100 µm; **p ≤ 0.01; one-way ANOVA (95% confidence; n = 5). 
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Figure 3.5. The effects of BDNF (5.71 nmol/kg) + ADTC5 (10 µmol/kg), BDNF alone (5.71 
nmol/kg), or vehicle treatments on mRNA expression of MAPK1, EGR1, ARC in the CA1 region 
of the hippocampus of the brains of APP/PS1 mice. (A) Photomicrograph of DAPI (grey), EGR1 
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(green), ARC (red), MAPK (cyan) and composite images taken of the hippocampus of APP/PS1 
mice treated with BDNF + ADTC5, BDNF alone, or vehicle. (B) Quantitative comparison of 
MAPK1 EGR, and ARC, and mRNA transcript expression, as determined by fluorescence 
intensity, for mice treated with BDNF + ADTC5, BDNF alone, or vehicle. Scale bar = 100 µm; 
p* ≤ .-5; ***p ≤ 0.001; one-way ANOVA (99% confidence; n = 4).  Contrast and brightness of 
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Chapter 4:  Time-Dependent Brain Delivery of Monoclonal Antibody and Its 
Clearance from the Brain 
4.1. Introduction: 
Monoclonal antibodies (mAbs) have been successfully used to treat patients with various 
diseases; however, they have not been successfully utilized to treat brain diseases. Several mAbs 
in clinical trials for treatment of central nervous system (CNS) diseases did not receive approval 
from the FDA due to their lack of efficacy.1 Because mAbs are designed with known targets and 
mechanisms, they are very attractive for development as therapeutic agents. In addition, they have 
excellent specificity, good half-lives, and low toxicity. There is a continued push to develop new 
mAbs for treating brain diseases, although most mAbs cannot efficiently cross the BBB. In 
addition, their brain diffusion and clearance properties have not been well studied. Therefore, there 
is an urgent need to study various methods to improve delivery of mAbs into the brain as well as 
their clearance from the brain. 
Many developed mAbs for brain diseases have good activity in in vitro and in vivo animal 
models during preclinical studies; they also frequently show ideal pharmacokinetic profiles in 
early clinical trials. Regardless of these promising early results, all have failed after phase-2 or -3 
clinical trials. As an example, seven different developed mAbs for Alzheimer’s disease that target 
different epitopes of amyloid-beta failed to received FDA approval.2 More recently, the clinical 
trial of anti-Tau mAb (8E12) was halted during phase-2 clinical trial after the data showed 
insufficient benefits to patients.3 Because of insufficient efficacy in multiple sclerosis (MS) 
patients, clinical trials of four mAbs, anti-Nogo-A, anti-LINGO-1, sHIgM22, and VX15/2503 for 
inducing remyelination, were halted.4-7 The inability of mAbs to cross the BBB could be one of 
   135 
the potential reasons for their low efficacy. In addition, clearance from the brain could be an 
important factor that influences the biological activity of mAbs in the brain. 
Several methods have been investigated to improve brain delivery of mAbs as therapeutics. 
Brain delivery of 2.5 mg/kg bevacizumab using the osmotic BBB disruption (BBBD) method has 
been investigated in two pediatric patients with refractory radiation necrosis. After treatment, the  
patients could regain muscle strength.8 Although BBBD has demonstrated effectiveness in general, 
some patients have developed complications such as anaphylaxis, seizures, and cerebral edema.9  
A combination of focused ultrasound (FUS) and microbubbles for brain delivery of drugs and the 
repeated use of this method has been shown to be safe in non-human primates; however, the use 
of FUS has not been evaluated in humans.10  
Our group has recently demonstrated that cadherin peptides can be used as BBB modulators 
(BBBM). They have been shown to significantly enhance in vivo delivery of small to large 
molecules, including lysozyme, brain-derived neurotrophic factor (BDNF), and albumin, IgG mAb 
into the brain in mice.11-16 Although many studies have focused on the delivery of mAbs into the 
brain, the data on mAb brain clearance after delivery are still limited. In this study, we examined 
the time-dependent IgG mAb delivery and its clearance from the brain. A combination of IgG mAb 
and ADTC5 or IgG mAb alone also was administered via i.v. in C57BL/6 mice, and the circulation 
time in the blood after administration was varied between 0.25 and 72 h. Then, the mAb 
depositions in the brain, liver, kidney, lung, spleen, and heart were quantified using near IR 
fluorescence (NIRF) imaging. Finally, the duration of the BBB opening created by ADTC5 peptide 
to allow IgG mAb penetration into the brain was evaluated by pretreatment with ADTC5 followed 
by administration of mAb delayed for 0, 20, or 40 min.  
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4.2. Materials and Methods: 
4.2.1. Chemicals and Reagents: 
The solvents and reagents for peptide synthesis and purification were purchased from Sigma 
Aldrich Chemical Company (St. Louis, MO) and Fisher Scientific, Inc. (Hampton, NH). The Fmoc 
amino acids used for the automated peptide synthesizer were purchased from Gyros Protein 
Technologies, Inc. (Tucson, AZ). The IRdye800CW Donkey anti-Goat IgG was acquired from LI-
COR, Inc. (Lincoln, NE).  
 
4.2.2. Peptide Synthesis and Purification: 
The synthesis linear peptide precursor to cyclic ADTC5 peptide was accomplished using an 
automated Tribute solid-phase peptide synthesizer (Gyros Protein Technologies, Inc.). The peptide 
was cleaved from the resin using a trifluoro acetic acid (TFA) solution containing scavengers such 
as phenol, tri-isopropyl silane (TIPS), and water. TFA solution was added to cold diethyl ether to 
precipitate the peptide as a crude product. After filtration, the crude peptide was purified using 
semi-preparative HPLC with a C18 column Waters XBridge C18 (19 mm × 250 mm, 5 μm particle 
size; Waters Corporation, Milford, MA). The purified linear peptide precursor was dissolved in 
high dilution with bicarbonate buffer solution at pH 9.0, and the solution was bubbled with air to 
oxidize the two thiol groups to make a cyclic peptide with disulfide bond. The procedure produced 
a cyclic peptide monomer as a major product with low amounts of dimers and oligomers. Similar 
to the linear precursor, the cyclic monomer was purified using semi-preparative HPLC. The purity 
of each isolated fraction was determined by analytical HPLC using a C18 column (Luna C18: 4.6 
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mm × 250 mm, 5 μm particle size, 100 Å; Phenomenex, Inc., Torrance, CA) followed by peptide 
identification using time-of-flight mass spectrometry. 
4.2.3. Animals: 
 
C57BL/6 mice were used in this study, and each experiment utilized 3 mice per group (n = 3) 
using a random selection of male and female with similar body weights for each group. The animal 
studies were done according to an animal protocol approved by the Institutional Animal Care and 
Use Committee (IACUC) at The University of Kansas. The animals were housed and cared for by 
personnel of the Animal Care Unit under the supervision of attending veterinarians. 
 
4.2.4. Preparation of Stock Solutions and Calibration Curves: 
 
The stock solution of IRDye800CW-IgG mAb was prepared and stored at –80 °C prior to serial 
dilution using phosphate-buffered saline (PBS) to generate standard solutions with various 
concentrations. After standard solutions of IgG mAb were prepared, 10 µL of each standard 
solution was added into 200 μL of blank brain homogenates. Then, each spiked brain homogenate 
(n = 3) was scanned using a Licor Odyssey CLx imaging system (Licor, Lincoln, NE) to acquire 
the NIRF signal intensity from the IgG mAb. The result produces a linear correlation between 
NIRF signals and IgG mAb concentrations from 0.5 to 50 ng/mL. To quantify the amount of IgG 
mAb in the brain, the brain was homogenized in 2.0 mL PBS by mechanical disruption, and three 
200 μL samples (n = 3) from a brain homogenate were added into different wells. Each well was 
scanned for NIRF signal using the Odyssey CLx scanner. Finally, the detected NIRF signal 
intensity was interpolated into the calibration curve to determine the amount of IgG mAb in pmol 
per gram brain. 
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4.2.5. Time-Dependent Brain Delivery IRdye800CW-IgG mAb using ADTC5 in C57BL/6 
Mice: 
The effects of time-dependent brain delivery of IgG mAb using ADTC5 were assessed in 
C57BL/6 mice with 3 mice/group (n = 3). The depositions of IgG mAb in the brains and other 
organs were quantitatively determined using NIRF imaging using an Odyssey CLx scanner. For 
each study, the animal was injected i.v. via tail vein with 21.6 nmol/kg IRdyeR800CW-IgG mAb 
with or without 13 µmol/kg ADTC5. The first study was accomplished for evaluating the effects 
of circulation time on IgG mAb depositions in the brain and other organs (liver, kidney, spleen, 
lung, and heart). Six groups of mice were administered a single dose of IgG mAb + ADTC5 while 
another six groups were administered with IgG mAb alone. A pair of IgG mAb + ADTC5 and IgG 
alone groups were sacrificed after various circulation times at 0.25, 1, 2, 24, 48, and 72 h. After 
sacrifice, each mouse was subjected to a trans-cardiac perfusion process using PBS with 0.5% 
Tween-20 to remove excess IgG mAb in brain capillaries to prevent false positive detection. The 
brain and other organs were then harvested and rinsed with PBS. Protein depositions in the brain 
and other organs were quantified by NIRF imaging using an Odyssey CLx NIRF scanner. 
The second study was carried out to determine the duration of BBB modulation induced by 
ADTC5 that allows permeation of IgG mAb across the BBB. In this case, the IgG mAb was 
administered via i.v. injection 20 or 40 min after administration of ADTC5. Then, 15 min after 
injection of IgG mAb, the mice were sacrificed followed by trans-cardiac perfusion process. The 
brain was isolated for quantification of IgG mAb deposition. 
 
4.2.6. Capillary Depletion Method: 
 
To ensure that the brain perfusion method was effective in removing the delivered mAb from 
the microvessel endothelial cells, capillary depletion experiments were performed to compare the 
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brain deposition of the protein in brain homogenates with and without microvessel endothelial 
cells using the previous method.11, 14  
 
4.2.7. Data Processing and Statistical Analysis: 
 
All data were processed using Graphpad Prism (San Diego, CA), and PKsolver. The data from 
the circulation time-based brain delivery of IgG mAb with or without ADTC5 were compared 
using ANOVA with Holm-Sidak post-hoc tests for multiple comparisons or t-Tests.  Statistical 
significance was determined by correcting for multiple comparisons using the Holm-Sidak 
method. A p-value of < 0.05 was the criterion for statistical significance. Outliers were removed 




4.3.1. Time-dependent Brain Deposition of IgG mAb: 
 
To quantitatively determine the brain deposition of IgG mAb, a calibration curve was 
generated with excellent linearity of R2 > 0.99. The amounts of delivered IgG mAb were 
determined by interpolating the NIRF signal intensity onto the calibration curve. A capillary 
depletion experiment was carried out to ensure that there was no remaining IgG mAb in the brain 
capillaries. The result showed that there was less than 2% difference between capillary depleted 
and non-depleted brain homogenates, suggesting that the brain perfusion method was efficient in 
removing the remaining IgG mAb from the brain capillaries. 
The effects of ADTC5 and various circulation times on IgG mAb brain depositions were 
assessed.  At 0.25-h circulation time, the brain amount(s) of IgG mAb was significantly higher 
when delivered along with ADTC5 compared to that of IgG mAb alone (Table 4.1, Figure 4.1). 
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The qualitative NIRF images of the brains after time-dependent treatments with IgG + mAb and 
IgG alone were clearly distinguishable (Figure 4.1A). The quantitative comparisons of time-
dependent brain depositions of IgG mAb after administrations over a 72-h time period are shown 
in Figure 4.1B. In the IgG mAb + ADTC5 group after 0.25 h circulation time, the amount of IgG 
mAb in the brain was the highest, while the amount in the brain decreased rapidly when the 
circulation times were lengthened from 0.25 h to 2 h (Figure 4.1C; Table 4.1). From 2 to 48 h 
time points, the decrease in brain deposition was less dramatic than at the 0.25–2.0 h time points 
(Figure 4.1B).  There were significant differences in mAb brain depositions between the IgG mAb 
+ ADTC5 and IgG mAb groups at 0.25 or 1.0 h circulation times. However, these differences were 
less pronounced or not significant between 2 and 48 h circulation times. 
The time-dependent amounts of IgG mAb in the brains were used to estimate the half-lives 
(t1/2) of IgG mAb after delivery with and without ADTC5 (Figure 4.1B). There are two different 
phases found in the brain depositions of IgG mAb when delivered with ADTC5; thus, the estimated 
t1/2alpha and t1/2beta of IgG mAb when delivered with ADTC5 were 0.34 ± 0.22 h and 65.50 ± 12.09 
h, respectively. In contrast, the half-life for IgG mAb when delivered alone was 58.60 ± 10.62 h. 
 
4.3.2. Depositions of IgG mAb in Other Organs: 
 
The effects of ADTC5 on depositions of IgG mAb in other organs such as liver, spleen, kidney, 
lung, and heart were compared to control, and quantifications were done using NIRF intensities 
on different organs (Figure 4.2). Qualitatively in the NIRF images, the majority of the IgG mAb 
was found in the liver compared to other organs such as spleen, kidney, lungs, and heart of animals 
treated with IgG mAb + ADTC5 (Figure 4.2A) and IgG mAb alone (Figure 4.2B). Quantitative 
determinations showed that the depositions in the liver have the highest peak at the 1-h time point, 
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and decrease dramatically after the 2-h time point and continually decline for over 72 h. In addition, 
there were no significant differences in the liver depositions of IgG mAb between groups treated 
with mAb + ADTC5 and mAb alone over the 72-h time points (Figure 4.2C & D). These results 
indicate that ADTC5 did not influence the deposition of IgG mAb in the liver.  
The effects of ADTC5 on IgG mAb depositions in spleen, kidney, lungs, and heart were also 
compared in the presence or absence of ADTC5 (Figure 4.2E). The deposition of IgG mAb was 
higher in all four organs at the 2-h time point, and the amounts of IgG mAb in these four organs 
dropped at the 24-, 48-, and 72-h time points. There were no statistical differences found in the 
spleen, kidney, lung, and heart of mice treated with ADTC5 + IgG mAb or IgG mAb alone. 
The comparisons of time-dependent brain and liver depositions are shown in Figure 4.3. It 
was interesting to find that the IgG mAb brain deposition peaked at 0.25-h circulation time while 
the deposition in the liver peaked at the 2-h circulation time. This suggests that clearance by the 
liver may influence the time-dependent IgG mAb deposition in the brain. These comparisons 
showed that ADTC5 had a big impact on the delivery of IgG mAb into the brain but not into the 
liver. 
 
4.3.3. Duration of BBB modulation for IgG mAb Brain Delivery: 
 
The duration of pore openings in the BBB intercellular junctions created by ADTC5 was 
evaluated using a 20- or 40-min delay between the administrations of ADTC5 and IgG mAb. As a 
negative control, IgG mAb was administered alone via i.v. (Figure 4.4). The delivered molecules 
were allowed to circulate for 15 min; then, the animals were sacrificed, followed by quantification 
of IgG mAb in the brain. In the groups without delay in administration, there was a significant 
amount of IgG mAb in the brains of the mAb +ADTC5 group compared to mAb control alone 
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(Figure 4.4). Compared to IgG mAb alone group (4.01 ± 1.08 pmol/g brain), there were no 
significant differences between mice that received IgG mAb after a 20-min (4.02 ± 2.72 pmol/g 
brain) or 40-min (2.62 ± 0.40 pmol/g) delay. The result suggests that the BBB pore opening was 




There is a considerable degree of interest and effort by the pharmaceutical industry to utilize 
mAbs for the treatment of brain diseases because they are normally designed for ah known target 
molecule with a specific function(s) or mechanism of action. Thus, mAbs normally have high 
specificity, low side effects, and an extended half-life. Many mAbs have been evaluated in clinics, 
but many of those have not been successful in showing the expected efficacies and benefits to 
patients with brain diseases. The physicochemical properties of mAbs are not favorable for passive 
diffusion through the transcellular pathway because they cannot readily partition into the cell 
membranes of the BBB endothelial cells. Similarly, the presence of the tight junctions inhibits 
them from passively diffusing through the paracellular pathways of the BBB. Alternatively, mAbs 
can cross the BBB via pinocytosis or receptor-mediated endocytosis. Although these processes 
have been exploited to deliver mAbs, success in improving mAb brain delivery has been limited 
due to the possible low efficiency in transporting the mAb from the blood into the brain. 
In this study, the brain delivery of mAb has been accomplished using ADTC5, which inhibits 
cadherin-cadherin interactions at the adherens junctions to increase the porosity of the BBB 
paracellular pathways. ADTC5 significantly increased brain depositions of IgG mAb after i.v. 
administration compared to IgG mAb alone. It is interesting to find that the IgG mAb brain 
deposition was the highest when the circulation time was 0.25 h and, as the circulation time was 
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increased, the brain deposition also decreased. After 2 h circulation time, the differences in IgG 
mAb brain depositions were no longer significant between IgG mAb + ADTC5 and IgG mAb 
alone. After 72 hours, there was essentially no detectable difference between delivery of IgG 
peptide and IgG control. These results indicate that IgG mAb was rapidly cleared from the brain. 
Our previous studies using magnetic resonance imaging (MRI) showed that  BBB modulation 
using ADTC5 was rapid (within a matter of minutes); when a combination  of 65 kDa galbumin + 
ADTC5 was administered via i.v., a significant brain deposition of galbumin was observed within 
3 min compared to when control galbumin was administered alone.14  To evaluate the transient 
and reversible modulation of the BBB by ADTC5, pretreatment studies were carried out. In this 
study, the animals were first treated with ADTC5 and, after a certain delay period, galbumin was 
administered, followed by brain scanning using MRI. When the delay was 10 min, a significant 
amount of galbumin was observed in the brain.14 However, when the delay was increased to 40 
min, the amount of galbumin observed in the brain was similar to that seen in control.14 These 
results indicated that the BBB modulation was transient and reversible and the BBB pore opening 
for molecules the size of 65 kDa galbumin was between 10 to 40 min. In the current study, we also 
determined the duration of BBB opening for 150 kDa IgG mAb. The result showed that 20- or 40-
min delay after treatment with ADTC5 did not allow the IgG to enter the brain (Figure 4.4). This 
indicates that large paracellular pores created by ADTC5 to allow IgG mAb to enter the brain 
collapsed in less than 20 min. A previous study has shown that ADTC5 cannot enhance the 
delivery of 220 kDa fibronectin, indicating that there is a molecular weight limit for the pore 
opening by ADTC5.15 In summary, the effect of ADTC5 in opening the BBB was fast and the 
duration of opening was 20 min or less. Thus, there is a time- and molecular size-dependent 
opening in the BBB paracellular pathway created by ADTC5. 
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ADTC5 and HAV6 peptides have been compared when delivering various sized proteins such 
as 15 kDa lysozyme, 65 kDa albumin, 150 kDa mAb, and 220 kDa fibronectin at a dose of 21.6 
nmol/kg. ADTC5 enhanced the brain delivery of lysozyme, albumin, and mAb but not fibronectin 
in C57BL/6 mice.15 In contrast, HAV6 peptide delivered lysozyme but not albumin and IgG mAb 
into the mouse brains of mice. In a separate study, HAV6 delivered galbumin to the brain when it 
was administered at 600 nmol/kg, which was 27 times the dose of albumin (21.6 nmol/kg).14 It 
was interesting to find that new cyclic peptides (HAVN1 and HAVN2) derived from HAV6 with 
N- to C-terminal cyclization can improve the brain delivery of IgG mAb compared to control.16 
Linear and cyclic ADTHAV peptides with combination sequences from HAV6 and ADTC5 were 
shown to be very effective in delivering IgG mAb into the brain.16  These results suggest that there 
is a size-dependent delivery by cadherin peptides as BBB modulators. It was also found that the 
dose of delivered protein can influence its deposition in the brain. It is proposed that the difference 
in the modulatory activities of cadherin peptides were due to their binding mechanisms to 
cadherins in the intercellular junctions of the BBB.  
There are many unknown aspects of the way that mAbs enter the brain from the systemic 
circulation as well as their clearance from the brain. A few studies have focused on the kinetics 
and mechanisms of clearance from the brain; thus, this information will be useful for optimizing 
the brain delivery and deposition of mAbs during treatments of brain diseases. It is unclear whether 
the mAb would have a different half-life in the CNS compared to in plasma. Two independent 
studies have demonstrated that the clearance of insulin administered to rat cerebral spinal fluid 
(CSF) to be either 13 or 21 mL/day/kg,17 whereas the clearance of IgM and IgG3 mAbs in rats was 
reported to be 42 and 101 mL/day/kg, respectively.18 A separate study was done to compare the 
clearance rates of IgG mAb and insulin by co-administering both proteins into the lateral ventricle; 
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following this, samples from CSF were collected at various time-points. The results showed that 
clearances of IgG mAb and insulin were 103 ml/day/kg and 129 ml/day/kg for IgG, respectively; 
the reported CSF half-lives for IgG mAb and insulin were 36.0 min and 43.2 min, respectively.19   
Our study showed that the half-life for IRdyeR800CW-IgG mAb (21.6 nmol/kg) delivered at 
a dose using ADTC5 was 0.34 ± 0.22 h (20 min) when determined between 0.25 to 2 h time points, 
and the second half-life was 65.50 ± 12.09 h when determined between 2–72 h time points. Chang 
et al. determined the half-life of trastuzumab (Herceptin®) in the brain to be 105 h when 
administered at a dose of 10 mg/kg (66 nmol/kg).6 Using microdialysis, the mAb half-lives were 
115 and 180 h, respectively, when the samples were collected from the lateral ventricle and cisterna 
magna. There is considerable variability in the reports of half-lives of protein clearance from the 
brain; one of the reasons is that some studies relied on determining the protein concentrations in 
the CSF without determining the time-dependence of protein depositions in brain tissue. The 
differences in method of delivery presumably contribute to the variability of depositions at 
different regions of the brain. The mAb physicochemical properties and the availability of a mAb 
binding target will also influence its clearance from the brain. The administered dose and method 
of administration as well as location of mAb detection may contribute to the observed PK profiles. 
In our study, BBB modulation to deliver the mAb could contribute to the equilibrium process 
between the blood and the brain. The time-dependent rapid decrease in the brain deposition in the 
first 2 h could be due to mAb clearance through the CSF. It has been proposed that clearance of 
mAb from the brain could involve the participation of neonatal Fc receptors (FcRn) at the BBB. 
The clearance of many non-endogenous molecules from brain tissue to CSF after delivery 
across the BBB has been shown to be rapid and presumably via receptor and/or or equilibrium-
based flow of large molecules out of the brain tissue into CSF. The total estimated volume of CSF 
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in the human brain is approximately 140 mL, and it is estimated that in humans the entire CSF 
volume is produced and excreted into the blood every 4 to 5 hours.20 Noguchi et al. reported that 
a bulk flow clearance of mAb is 29.0 mL/day/kg.19 Thus, CSF is rapidly turned over, and molecules 
that are transferred into the CSF are transported to the blood rather quickly. However, the bulk 
flow and diffusion of molecules from brain tissue to CSF has not been widely studied. Blasberg et 
al. demonstrated that chemotherapy drugs administered intrathecally penetrate the brain 
parenchyma very slowly, and for each mm the distance from the CSF is increased, the penetration 
decreases logarithmically.21  Additionally, Krewson et al. (1995) demonstrated that when nerve 
growth factor (NGF) was administered directly to the brain interstitial tissue, it was generally  
transported only 2–3 mm in any direction from the site of implantation, with trace amounts found 
throughout the rest of the brain.22  
During administration of IgG mAb with and without ADTC5, the majority of the IgG mAb 
was deposited in the liver, with low amounts deposited in the kidney, heart, lung, and spleen. There 
was no effect of ADTC5 peptide on IgG mAb depositions the liver, kidney, spleen, lung, and heart  
(Figure 4.2). In a comparison of time-dependent IgG mAb depositions in the brain and liver, the 
highest deposition of IgG mAb was at the 0.25-h time point when the deposition in the liver was 
still low (Figure 4.3). When the deposition of IgG mAb in the brain dropped at the 2-h time point, 
the deposition in the liver was at the maximum level. A similar trend was found in kidney, spleen, 
lung, and heart. These results suggest that there is a possible correlation between the clearance of 
IgG mAb from the brain and increased deposition in the liver. 
Cadherin peptides have been used to deliver therapeutic agents into the brains of animal models 
of brain diseases.  HAV6  peptide delivers significant amounts of an anticancer drug, adenanthin, 
to the brains of mice with medulloblastoma brain tumors (D425 tumor cells).23 Treatments with a 
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combination of HAV6 and adenanthin decreased tumor load and increased survival rate in 
medulloblastoma mice compared to those treated with adenanthin alone or untreated mice.23 In a 
separate study, ADTC5 was used to deliver brain-derived neurotrophic factor (BDNF) to prevent 
disease relapse in the experimental autoimmune encephalomyelitis (EAE) animal model compared 
to BDNF alone, ADTC5 alone, and PBS. Pathology evaluations of the brains indicated that a 
combination of BDNF and ADTC5 significantly promotes remyelination, upregulates NG2 cells, 
and activates downstream cellular processes in SJL mice compared with those treated with BDNF 
alone or untreated mice. Most recently, we have demonstrated that BDNF delivery in conjunction 
with ADTC5 can improve cognitive performance in APP/PS1 mice, a model for Alzheimer’s 
disease.  The recent success in delivering therapeutically relevant molecules implies that molecules 
of various sizes can be broadly delivered across the BBB in therapeutically relevant doses in part 
due to the vast degree of vasculature in the brain (over 400 miles of capillary tissue). When this is 
compared to the approximate surface area of the choroid plexus (0.021 m2) where CSF is produced, 
it is clear how there can be an advantage for delivering molecules across the BBB rather than via 
absorption from CSF.  Although the mechanisms by which ADTC5 and other cadherin peptides 
modulate the BBB is relatively well understood, how the delivered protein molecules, especially 
IgG mAbs, are shuttled out of the brain or whether BBB modulation plays a role is yet to be 
determined. Future studies probing whether ADTC5 has residual effects on clearance of molecules 
from the brain may provide insight on how to optimize the transport of mAb and other proteins 
into, within, and out of the brain.  
The binding mechanisms of cadherin peptides (i.e., HAV6 and ADTC5 peptides) to the 
extracellular 1 (EC1) domain of E-cadherin have been determined using heteronuclear 1H, 15N- 
heteronuclear single quantum coherence (1H, 15N-HSQC) NMR spectroscopy and molecular 
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docking experiments.24 The results indicated that HAV6 and ADTC5 peptides have different 
binding sides on the EC1 domain of E-cadherin. Utilizing the X-ray crystal structure of C-cadherin, 
homophilic interactions of cadherins can be divided into cis and trans interactions. The cis 
interaction occurs when an EC1 domain from one cadherin protein binds to an EC2 domain of 
another cadherin from the same cell membranes. The trans interaction is when an EC1 domain of 
one cadherin from a membrane of one cell binds to an EC1 domain of another cadherin from the 
opposing cell. It is hypothesized that HAV6 binds at the EC1 domain surface to inhibit the cis 
interaction between EC1 and EC2 domains of two neighbor cadherins from the same cell 
membranes. In contrast, it is hypothesized that ADTC5 peptide binds to a hydrophobic pocket of 
the EC1 domain to block the trans-EC1-EC1 interactions of cadherins from cell membranes of the 
opposite cells in a manner that blocks the trans interaction. Thus, it is proposed that the pore sizes 
that were created by ADTC5 were larger than those created by HAV6 due to inhibition of trans 
interactions compared to the inhibition of cis-interactions. Studies to test the proposed hypotheses 




In this study, we found that ADTC5 enhanced delivery of IgG mAb into the brain and that the 
circulation time influenced the brain deposition. When the circulation time was increased, the brain 
deposition of IgG mAb was decreased, indicating a time-dependent clearance of IgG mAb from 
the brain. The deposition of IgG mAb in the brain dropped quickly when circulation time was 
increased within a 2-h period. The window of BBB opening caused by ADTC5 was less than 20 
min. During the circulation of the IgG mAb, the majority of IgG mAb was deposited in the liver 
with limited amounts in the kidney, spleen, lung, and heart. There was no effect of ADTC5 on the 
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depositions of mAb in the liver, kidney, lung, spleen, or heart. In the future, there is a need to study 
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4.6. Tables, Figures, and Figure Legends: 
 
Table 4.1. Circulation time-dependent IgG mAb brain depositions upon delivery with 
and without ADTC5 
Circulation 
Time 
ADTC5 pmol/g (mean ± SD) Control pmol/g (mean ± SD) p value 
0.25 h 13.32 ± 1.93 4.01 ± 1.08 0.0001**** 
1 h 8.23 ± 1.81 2.96 ± 0.34 0.0001**** 
2 h 5.73 ± 1.62 4.21 ± 2.12 0.25 
24 h 4.40 ± 1.07 2.42 ± 0.45 0.09 
48 h 3.49 ± 0.35 2.16 ± 0.04 0.33 
72 h 1.69 ± 0.36 1.43 ± 0.22 0.94 
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Figure 4.1. The effects of ADTC5 on the deposition of IRdye800CW-IgG mAb in the brain from 
0.25 to 72-h circulation time period. Brain depositions were determined qualitatively and 
quantitatively in pmol/g brain using NIRF imaging after delivery of IgG mAb alone (21.6 nmol/kg) 
or with ADTC5 (13 µmol/kg). (A) The NIRF images of intact brains after delivery of IgG mAb 
with ADTC5 (left) and IgG alone as control (right). The yellow-red colors represent the brain 
depositions of IgG mAb with a dark blue color as a background of brain tissues.  (B) The 
quantitative amounts of IRdye800CW-IgG mAb in the brain over a 72-h time period. (C) The 
expansion of brain depositions of IRdye800CW-IgG mAb over the first 2-h time period. The 
asterisk (*) designates a significant difference between mice dosed with or without ADTC5. Data 
are shown as mean ± SD with the number of animals, n = 3, for each time point of each group. 
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Figure 4.2. The depositions of IRdye800CW-IgG mAb in liver, spleen, kidney, lung, and heart 
after i.v. administrations with or without ADTC5 between circulation times of 0.25 and 72 h.  (A 
& B) The qualitative NIRF images show IgG mAb depositions in liver, spleen, kidney, lung, and 
heart tissues after administrations of (A) IgG mAb + ADTC5 and (B) IgG mAb alone. The yellow-
red colors indicate depositions of IgG mAb and the dark blue color is the background of organ 
tissues. (C) Comparisons of quantitative NIRF signals from IgG mAb in the liver, spleen, kidney, 
lung, and heart tissues. The majority of depositions were found in the liver. There were no 
significant differences in the liver depositions of IgG mAb when delivered with and without 
ADTC5. (D) The expansion of liver depositions between 0.25–2.0 h show that there was no effect 
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of ADTC5 on IgG mAb deposition in liver. (E) Comparisons of IgG mAb depositions in spleen, 
kidney, lungs, and heart when delivered with ADTC5 between 0.25 and 2 h (left) and between 24 
and 72 h (right). There were no significant differences in IgG mAb depositions in spleen, kidney, 
lung, and heart between ADTC-treated and control mice over 72 h. Organ deposition was 
quantitatively determined by NIRF signal intensities for all organs. Data are shown as mean ± SD 
with the number of animals, n = 3, for each time point of each group. 
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Figure 4.3. Comparisons between brain and liver depositions when IRdye800CW-IgG mAb was 
administered with and without ADTC5. (A) ADTC5 enhanced the brain depositions of IgG mAb 
compared to control but did not have any effect on the deposition of IgG mAb in the liver in the 
0.25–2.0 h time period. The peak of IgG mAb in the liver was at 2 h circulation time. (B) There 
were no significant enhancements of IgG mAb by ADTC5 in the brain and liver when monitored 
between 24 – 48 h time period. Data are shown as mean ± SD with the number of animals, n = 3, 
for each time point of each group. 
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Figure 4.4. The effects of 0, 20, and 40 min delay between the delivery of ADTC5 (13 µmol/kg) 
and IRdye800CW-IgG mAb (21.6 nmol/kg) to evaluate the time-dependent paracellular pore 
opening for allowing IgG mAb to enter the brain. The IgG mAb was allowed to circulate for 15 
min prior to animal sacrifice for quantification of its deposition in the brain using NIRF imagin. A 
significant enhancement of brain deposition of IgG mAb was observed when IgG mAb and 
ADTC5 were delivered together compared to when IgG mAb was delivered alone. A delay of 20 
or 40 min in delivering IgG mAb after administration of ADTC5 resulted in no significant 
differences in IgG mAb depositions compared to control IgG mAb alone.  This indicates that the 
BBB pore opening was closed at 20 min or less for 150 kDa IgG mAb.  The asterisk (*) designates 
a significant difference between mice dosed with IgG mAb + ADTC5 and those receiving IgG 
mAb alone. Data are shown as mean ± SD with the number of animals, with n = 3 for each time 
point of each group. 
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Chapter 5: Summary and Future Directions 
5.1. Summary: 
The goal of this project was to enhance the delivery of the neurodegenerative protein, brain 
derived neurotrophic factor BDNF, and to further understand the dynamics of antibody delivery 
to the brain. The aims were to (i) deliver BDNF across the blood–brain barrier (BBB) via the use 
of ADTC5 peptide in EAE mice and evaluate if BDNF can be delivered in a therapeutically 
relevant dose, (ii) expand BDNF delivery to a separate animal model to evaluate BDNF use as a 
potential therapeutic for Alzheimer’s disease, (iii) to evaluate the pharmacokinetics of an IgG 
monoclonal antibody (mAb) in the brain to further understand how they can be used as a 
therapeutic for brain disease.  The BBB limits the penetration of protein therapeutics into the brain, 
making it difficult to deliver diagnostics and therapeutics into the brain. How the integrity of the 
BBB changes with brain disease has been previously evaluated and has been thought to be highly 
disrupted in Alzheimer’s and multiple sclerosis (MS); however, we demonstrated the BBB of EAE 
and APP/PS1 mice is intact enough so that BDNF cannot penetrate the brain on its own.1-4  
In the second chapter of this dissertation, we demonstrated that ADTC5 could be used to 
enhance the delivery of BDNF to EAE mice and that repeated administration of BDNF + ADTC5 
could be used to treat the disease and prevent disease relapse. The mice that received BDNF + 
ADTC5 improved significantly in clinical body score compared to mice that received BDNF alone, 
ADTC5 alone, or vehicle. Furthermore, mice that received BDNF + ADTC5 showed increased 
myelin levels in the lateral corpus callosum, increased NG2 glia in the medial corpus callosum, 
and upregulated mRNA transcripts for early growth response-1 (EGR1) and activity-related 
cytoskeleton associated protein (ARC). To confirm directly that BDNF was entering the brain, 
BDNF was administered with or without ADTC5 to healthy mice and then detected using western 
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blot; there were clear BDNF bands in the brain homogenates of mice that received BDNF + 
ADTC5, whereas the bands representing mice that received BDNF alone showed virtually no 
detectable signal. 
In the third chapter, we demonstrated that the ADTC5 + BDNF delivery combination could be 
used to ameliorate the disease in a transgenic Alzheimer’s mouse model (APP/PS1). To initially 
assess BDNF’s efficacy in the APP/PS1 model, we administered repeated doses of BDNF + 
ADTC5, BDNF alone, or vehicle and subjected mice to behavioral/cognitive assessments. We 
showed that mice that received BDNF + ADTC5 performed significantly better in both the Y-
maze and novel object recognition (NOR) assessments compared to mice that received BDNF 
alone or vehicle. Similar to the EAE mouse model, we also showed an increase in NG2 glia in the 
cortex and upregulation of EGR1 and ARC mRNA transcripts in the cortex. We also probed for 
amyloid-beta plaques using a Congo red stain and saw high plaque loads in all mice groups, 
indicating BDNF is improving cognitive function likely by improving synaptic plasticity via NG2 
glia and not by reducing plaque load. 
In the fourth chapter, we wanted to further understand the pharmacokinetics of IgG mAbs 
when delivered to the brain via ADTC5. We recently demonstrated in separate experiments that 
ADTC5 along with other cyclic and linear peptides could significantly enhance brain deposition 
in mice of a near infrared fluorescent (NIRF) antibody, IRDye800CW-IgG mAb.5,6  We discovered 
an increased in circulation time of IRDye800CW-IgG + ADTC5 resulted in a decreased deposition 
into the brain, indicating that there is a rapid time-dependent clearance from the brain with a 
majority of the clearance occurring in the liver. We also discovered that across a 72-hour 
circulation time period, ADTC5 does not significantly enhance antibody deposition in peripheral 
organs. The last point of interest was determining how long the BBB remains open for an antibody 
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to penetrate. Previously, it has been shown that for 65 kDa galbumin, the BBB remains open 
between 10 to 40 minutes.7 However, for an antibody, we discovered the  BBB only remains open 
for in less than 20 min, indicating the effect of ADTC5 is short lasting for delivering mAb. A more 
specific time point will be evaluated in the future using MRI. 
 
5.2. Future Directions: 
5.2.1. Brain Delivery of Various mAbs and Fab Fragments: 
We chose to deliver the donkey–anti-goat IRDye800CW-IgG because it had no specific target 
in mouse and thus served as a freely circulating mAb, making it ideal for studying deposition into 
the brain and peripheral organs with or without ADTC5. There are several mAbs on the market 
that demonstrate excellent selectivity and efficacy for the treatment of various disease; however, 
none of these mAbs can readily enter the brain.8 Others have demonstrated the use of hypertonic 
mannitol to improve the delivery of bevacizumab and cetuximab for the treatment of cancers; 
however, there are known complications with using hypertonic mannitol, making repeated 
administration risky.9 It has been previously demonstrated via MRI that ADTC5 does not 
significantly alter cerebral blood flow10 and that cadherin peptides can be used enhance the 
delivery of anticancer drug, adenathin for the treatment of medulloblastoma in mice.11 Given the 
ability for ADTC5 to enhance antibody deposition into the brain, there is good reason to believe 
ADTC5 can improve the delivery of functional mAbs such bevacizumab or ranibizumab to treat a 
mouse model for brain tumors. Additionally, ADTC5 can likely be used to improve the delivery 
of an anti-Aβ mAb to reduce plaque load in APP/PS1. An important aspect would be to see if mice 
cognitively improve with the reduction of amyloid-β mAb and if there is associated cellular signals 
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indicating an improvement in brain health. The significance of amyloid-β versus Tau plaques is 
highly debated amongst industry, medical, and academic professionals.12 
 
5.2.2. Mechanisms of mAb Efflux Out of the Brain: 
We demonstrated that the presence of a delivered antibody to the brain is relatively short lived. 
It is known that the CSF half-life in mice and humans is very rapid, with a complete turnover 
happening every 4 to 5 hours.13,14 There has been extensive studies of antibody receptors on the 
systemic side of the BBB with hopes to exploit them to deliver antibodies to the brain.15 However, 
the means by which antibodies are expelled out of the brain has only been evaluated on by a few 
different groups16,17 Antibodies are thought to be shuffled out of the CNS via neonatal Fc receptors  
(FcRn); however, the kinetics and saturation limits of these receptors toward various mAbs are 
unknown. Additionally, it is not known whether ADTC5 can affect antibody efflux from the brain 
or rather just the influx. One way to probe at this would be to deliver an fluorescently labeled 
antibody via ICV, and to administer ADTC5 systemically to see if there is a modulated efflux from 
the brain. Additionally, the antibody can also be administered ICV with or without ADTC5 to  
observe the effect of ADTC5 on mAb clearance from the brain. Taken together, it is important to 
understand the dynamics of antibodies in the brain in order to improve dosing regiments, antibody 
design, and BBB modulation parameters in order to optimize mAb pharmacokinetic profiles for 
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